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ABSTRACT 
 
IDENTIFICATION OF THE INTERACTING DOMAIN OF p53 
FAMILY PROTEINS WITH p33ING1 
 
DENİZ DİNÇEL 
 
M.S. in Molecular Biology and Genetics 
Supervisor: Assist. Prof. Rengül Çetin-Atalay 
January 2002, 106 Pages 
 
p53 is a tumor suppressor gene, which is mutated, in about 50% of human 
cancers. The product of p53 gene encodes a sequence specific transcription factor. 
The genes transactivated by p53 code for proteins that are implicated in the negative 
regulation of cell proliferation and DNA damage repair. Two proteins, p63 and p73 
members of p53 family, show striking homology to p53. p53 protein interacts with 
several viral and cellular proteins and these interactions are important in the 
regulation and dysregulation of the functions of p53. Another gene named, ING1 was 
identified as a candidate tumor suppressor gene due to its functions in apoptosis and 
cell cycle arrest. p24ING1, one of the protein product of ING1, was shown to enhance 
the growth suppressor functions of p53. Furthermore a physical association between 
p53 and p33ING1, another ING1 transcript, proteins has been detected by 
immunoprecipitation. In this study, we investigated the physical interaction between 
p53 family proteins and p33ING1 using in vitro techniques in order to determine the 
region(s) of p53 family proteins and p33ING1 that enabled this interaction. As a 
preliminary step for the study, the wild-type p53 cDNA and its several deletion 
mutant constructs were used in GST pulldown assays and Far Western assays with 
purified GST-p33 protein to map the interacting region on p53 protein. New deletion 
mutant constructs of p53 protein were created and cloned into expression vectors for 
the detailed analysis of the interacting domain of p53 protein. Also the other members 
of p53 protein family, p63 and p73 were examined in vitro for interaction with 
p33ING1. Deletion mutants of these proteins were created and cloned into expression 
vectors for protein-protein interaction assays. The results of this study shows that p53 
protein interacts with p33ING1 and suggests that oligomerization domain of p53 
protein is needed for this interaction. In addition, for the first time, it was showed that 
p63 and p73 proteins interact with p33ING1 and in p63 the C-terminus region is the 
primary determinant region, involved in these interactions with p33ING1.  
 
Keywords: p33ING1, p53, p63, p73, tumor suppressor protein, protein-protein 
interaction,  GST pulldown, Far Western Blotting 
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ÖZET 
 
p53 PROTEİN AİLESİNİN p33ING1 PROTEİN’İ İLE İLİŞKİYE 
GİREN BÖLGESİNİN BELİRLENMESİ 
 
DENİZ DİNÇEL 
 
Yüksek Lisans Tezi, Moleküler Biyoloji ve Genetik 
Tez yöneticisi: Yard. Doç. Dr. Rengül Çetin-Atalay 
Ocak 2002, 106 Sayfa 
 
p53, insan kanserlerinin yaklaşık %50’sinde mutasyona uğrayan bir  tümör 
baskılayıcı gendir. p53 gen ürünü, DNA dizisi özgünlüğü olan bir transkripsiyon 
faktörüdür. p53 tarafından transkripsiyonu aktive edilen genlerin protein ürünleri, 
hücre bölünmesini önleyici yönde görev yapan kontrol elemanları ya da DNA tamir 
mekanizması elemanlarıdır. İki yeni protein, p63 ve p73 p53 protein ailesinin üyeleri, 
p53 proteinine hem gen seviyesinde hem de protein seviyesinde büyük benzerlik 
göstermektedir.p53 proteini bir çok hücresel ve viral protein ile etkileşime girer ve bu 
etkileşimler p53’ün işlevlerinin düzenlenmesinde ya da düzensizliğinde önemli yer 
tutar. ING1 (“Inhibitor of Growth 1”:Büyüme İnhibitörü 1) adlı yeni bir gen, apoptoz 
ve hücre döngüsün durdurulmasında ki rolleri dolayısıyla tümör baskılayıcı gen adayı 
olarak tanımlanmıştır. ING1’ın protein ürünlerinden biri olan p24ING1’ ın  p53’ün 
büyüme baskılayıcı işlevlerini arttırdığı gözlemlenmiştir. Dahası, p53 ile p33ING1, 
diğer bir ING1 proteın ürünü, arasında fiziksel bir etkileşim, immunopresipitasyon 
yöntemiyle belirlenmiştir. Bu çalışmada, p53 protein ailesinin üyelerinin, p33ING1 ile 
etkileşen bölgelerini belirlemek amacıyla bu proteinler arasındaki fiziksel etkileşimi 
in vitro yöntemlerle inceledik. İlk adım olarak, normal p53 cDNA’sı ve birçok 
değişik p53 delesyon mutantı cDNA’ları, p53’ün p33ING1 ile etkileşen bölgesini 
belirlemek amacıyla ‘GST pulldown’ sisteminde ve ‘Far Western Blotting’ 
sisteminde kullanılmıştır. Bu çalışmalardan elde edilen sonuçlara bağlı olarak iki yeni 
p53 delesyon mutantı yaratılmış ve protein-protein etkileşiminin belirlenmesinde 
kullanılmıştır. p53 protein ailesinin diğer iki üyesi olan p63 ve p73 proteinlerinin 
p33ING1 proteini ile etkileşimi ve etkileşim bölgeleri C-terminali delesyon mutantları 
yaratılarak incelenmiştir. Bu çalışmanın sonuçları p53 proteinin, p33ING1 ile 
oligomerizasyon bölgesi aracılığı ile etkileşime girdiğine işaret etmektedir. Buna ek 
olarak, p63 ve p73 proteinlerinin, p33ING1 proteini ile etkileşime girdiği ve bu 
etkileşimin p63 proteininin  C-terminalinden olduğu gösterilmiştir.  
 
Anahtar Kelimeler: p33ING1, p53, p63, p73, tümör baskılayıcı, protein-protein 
etkileşimi, GST-pulldown, Far Western Blotting 
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CHAPTER 1. INTRODUCTION 
 
1.1 General Introduction 
In an adult, the rates at which new cells in a tissue are formed and old cells die 
are in balance, producing a steady state in which the tissue does not increase in size. If 
the mechanisms regulating cell division are not functioning properly, the affected cells 
may produce new cells faster than old cells are removed, forming a growing mass of 
tissue known as a tumor. If the tumor cells grow into the surrounding tissues, disrupting 
their functions, and spread to other regions of the body, the tumor is said to be 
malignant tumor. Malignant tumors are composed of cancer cells, that have lost the 
ability to respond the normal mechanisms that regulate cell growth (Hanahan & 
Weinberg 2000). 
Two classes of genes are mutated in cancer formation. The first class of genes 
(gatekeepers) comprising tumor suppressor genes, directly controls cellular 
proliferation. They can do this either by controlling the rate of cell birth or the rate of 
cell death. The second class of genes (caretaker genes) does not directly control cell 
growth, but instead controls the rate of mutation. Cells with defective mutator genes 
acquire mutations in all genes including oncogenes and tumor suppressor genes at an 
elevated rate. This higher rate leads to accelerated tumorigenesis (for review see 
Vogelstein and Kinzler, 1998). 
Tumor suppressor gene is a genetic element whose loss or inactivation allows a 
cell to display one or another phenotype of neoplastic growth deregulation. The 
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products of the tumor suppressor genes are required for normal cell function, and they 
antagonize the proliferative actions of oncogenes to prevent tumorigenesis. Tumor 
suppressor mutations act as a recessive trait in the formation of tumors. Tumor 
suppressor genes constitute a very heterologous class of genes in terms of functions of 
their protein products. They can be transcription factors (e.g. p53, WT-1), cyclin 
dependent kinase inhibitors (e.g. p16) or receptor tyrosine kinases (e.g. RET) (for 
review see Haber, 1998).  
1.2 p53 Tumor Suppressor Gene and Protein Product 
1.2.1 Background 
p53 protein is known as guardian of the genome, functional inactivation of p53 
by gene mutation and deletion, protein degradation or viral oncogene binding renders a 
mammalian cell susceptible to oncogenic stimuli and environmental factors that 
promote growth deregulation and malignant progression. More than half of all human 
cancers shows either absence of p53 protein or mutations in this gene (for reviews, see 
Wang & Harris, 1997; Adams & Kaelin, 1998;  Ko & Prives, 1996) . p53 is a nuclear 
phosphoprotein. It was originally discovered in SV40-transformed cells, where it is 
associated with T antigen (Lane et al., 1979; Linzer et al., 1979). A large increase in the 
amount of p53 protein is found in many transformed cells or lines derived from tumors. 
In early experiments, the introduction of cloned p53 was found to immortalize cells. 
These experiments caused p53 to be classified as an oncogene, However subsequent 
studies revealed that p53 cDNAs used in these studies were mutant and wild type 
counterparts were shown to suppress the growth of transformed cells in vitro and 
tumorigenic potential of these cells in animals (Finlay et al., 1989). Mutations of p53 
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alleles were implicated in many human and animal tumors. Indeed, members of Li-
Fraumeni cancer-prone families were shown to carry germ-line p53 mutations (Malkin 
et al., 1990). The role of p53 in cancer was more directly accessed by the observation 
that p53 knock out mice developed tumors at high frequencies (Donehower et al., 
1992). Therefore, p53 was re-classified as a tumor suppressor gene.  
1.2.2 Cellular Functions of p53 protein 
The human p53 is located in the short arm of chromosome 17, 17p13.1. The 
gene has 11 exons and spans 20kb of genomic DNA. Many organisms have p53 
homologues, such as monkey, chicken, rat, frog, fruit fly and worm (Derry B. W., et al., 
2001; Jin S., et al., 2000; Soussi T., et al.,1988; Rigaudy P., et al.,1989). The general 
organization of the p53 protein is well conserved during evolution.  
p53 integrates signals from the cell’s internal and external environment to 
respond to inappropriate growth promoting or growth inhibiting conditions. The tumor 
suppressor activity of p53 stems from its ability to both inhibit the mitotic cell cycle and 
promote apoptosis. The functional character of the p53 protein was determined by 
experiments showing that p53 contains a strong transcriptional activation domain within 
its amino terminus and that it is a sequence specific DNA-binding protein (El-Deiry et 
al., 1992). Although the p53 protein acts as a transcriptional activator of genes 
containing p53 binding sites, it is also capable of inhibiting transcription from many 
genes lacking p53 binding sites. Several oncogenic DNA viruses express viral gene 
products that associate with and inhibit the trans-activation function of p53, notably 
SV40 large antigen, the adenovirus E1B 55-kD protein, and E6 protein of oncogenic 
forms of human papillomavirus (HPV E6) (for review, see Prives & Ko, 1996).  
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Figure 1.1: Upstream elements activating the p53 ( From Oren 1999). 
 
p53 plays multiple roles in cells. Expression of high levels of wild-type p53 has 
two outcomes: cell cycle arrest, or apoptosis. In unstressed cells, p53 appears to be 
present at low levels and exist in a latent inactive form that requires modification to 
become active. The types of modification that p53 is subject to seem to be stress-, 
species- and cell-type-specific. Levels and/or activity of p53 increase in response to 
DNA damaging agents (Maltzman and Czyzyk, 1984; Kastan et al., 1991), decreased 
oxygen (Graeber et al., 1994), oncogenic stimuli (Debbas and White, 1993), cell 
adhesion (Nigro et al., 1997), altered ribonucleotide pools (Linke et al., 1996), and 
redox stress (Hainaut et al., 1993) (Figure 1.1). The importance of p53 and 
modifications that affect its functions are not limited to malignant disease. The activity 
of p53 can increase in normal tissues when undergoing pathophysiological changes that 
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result in oxidative or redox stress, such as ischemia, reperfusion injury of the brain, 
heart, and other tissues.  
1.2.3 Structure of p53 protein 
The human p53 protein is a single polypeptide of 393 amino acids. It can be 
divided into different domains (for review, see Ko & Prives, 1996): at the N-terminus, a 
transactivation domain (residues 1 to 43) and proline-rich domain (residues 62 to 91); in 
the middle core, a DNA-binding domain (residues 100 to 300); and at the C-terminus, a 
tetramerization domain (residues 326 to 354) and a regulatory region (363 to 393) 
(Figure1.2). 
p53 binds in vitro to several proteins through its activation domain. The amino 
terminus of p53 interacts with many general transcription factors such as the TATA 
box-binding protein (TBP) component of general transcription factor TFIID, several 
TBP-associated factors (TAFs), including Drosophila  melanogaster TAF-40 and TAF-
60 (Thut et al., 1995), the human TAF-31 (Lu and Levine, 1995) and TFIIH (Xiao et 
al., 1994). p53 transcriptional activation is negatively regulated by the adenovirus E1B-
55Kd protein (Kao et al., 1990) and human Mdm2 protein (Haupt et al., 1997). In both 
cases, p53 amino acid residues 22 and 23 play a key role in the binding of p53 to E1B-
55Kd or Mdm2 protein. Thus the negative regulators of p53-mediated transcription 
target some of the same p53 amino acids critical to positive regulation of transcriptional 
activation. This evidence showed that p53 uses a hydrophobic interface in its N terminal 
domain to interact with the transcriptional machinery of the cell and its negative 
regulators. Also this domain is the target of phosphorylation by various kinases (for 
review, see Levine, 1997). 
6 
 
Proline rich region spans the amino acids 62-91. There are five tandemly 
repeated proline rich motifs in the form of PXXP (where P is proline and X is any 
amino acid) and these motifs were shown to bind SH3-containing proteins. This region 
is implicated in both growth arrest and apoptosis (Venot et al., 1998). 
The sequence-specific DNA-binding domain of p53 is localized between amino 
acid residues 100 and 300. It is a protease resistant and independently folded domain 
containing a Zinc ion that is required for its sequence-specific DNA-binding activity.  
 
 
 
Figure 1.2: Domain structure of p53 , together with mutational hotspots and interacting proteins. 
Dark Grey Boxes I-V: regions conserved among species; at the N-terminus: Transactivation domain; 
Next to it proline rich domain; In the middle of the protein: DNA binding domain ; At the C-terminus: 
there is both oligomrization and regulatory domain (Adapted from Ko & Prives 1996). 
 
 The p53 protein binds to four repeats of a consensus DNA sequence 5’-
PuPuPuC(A/T)-3’, and this sequence is repeated in two pairs each arranged as inverted 
repeats (El-Deiry et al., 1992). More than 90% of the missene mutations in the p53 
reside in this sequence-specific DNA-binding domain, and these mutations fall into two 
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classes: mutations which result in defective contacts with the DNA and loss of the 
ability of p53 to act as a transcription factor, or mutations which disrupt the three 
dimensional (3D) conformation of the protein (for review, see Levine, 1997). 
 The native p53 protein functions as a tetramer, and amino acid residues 326-354 
are required for this oligomerization of the protein. The structure of this domain 
contains a dimer of a dimer with two β sheets and two α helices. This tetramerization 
domain is linked to the sequence specific DNA-binding domain by a flexible linker of 
37 residues (Lee et al., 1994; Clore et al.,1995; Jeffery et al.,1995). 
 The C-terminus 26 amino acids form an open, protease sensitive, domain 
composed of nine basic amino acid residues that bind to DNA and RNA (Lee et al., 
1995). There is a considerable evidence showing that the p53 protein requires a 
structural change to activate it for sequence-specific binding to DNA. This non-DNA 
binding form can be regulated by basic C-terminus domain. Deletion of this domain, 
phosphorylation of certain residues by kinases, or by the binding of certain specific 
antibodies all activate site-specific DNA binding by the central domain (Hupp and 
Lane, 1994). Short (20-39 nucleotide) single strands of DNA interacting with this C-
terminus domain can also activate specific p53 DNA binding. The C-terminus domain 
helps to catalyze the reassociation of single-stranded DNA or RNA to double strands 
(Lee et al.,1995). It also binds preferentially to DNA ends and to internal deletion loops 
in DNA as generated by replication errors.  
1.2.4 Regulation of p53 Activity 
Because p53 is such a critical cellular protein, multiple mechanisms have 
evolved to regulate its activity. These regulatory mechanisms exist both tightly and 
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rapidly control the activities of p53 and to provide alternative regulatory mechanisms 
for different cell types and different physiological stimuli. Normally, in a cell, the p53 
protein is kept at a low concentration by its relatively short half-life. In addition to its 
low protein concentration, in some cells p53 probably also exists in a latent form 
(Kastan et al.,1991). To activate the protein, p53 must receive a signal or alternation. 
Several stressful situations, such as DNA damage, γ irradiation, presence of DNA repair 
intermediates after ultraviolet irradiation or chemical damage to DNA, can activate p53. 
This results in a rapid increase in the level of p53 in the cell and activation of a p53 as a 
transcription factor. Although levels of p53 mRNA does not change in response to 
stimuli, the levels of p53 protein increase rapidly (Kastan et al., 1991). The half-life of 
p53 increases several folds after DNA damage. Enhanced translation of p53 mRNA 
also contributes to this induction. Therefore the regulation is mainly posttranslational. 
This type of regulation is necessary for very rapid and efficient control of the p53 levels 
in a cell. In addition to changes in the level of p53, several different modifications are 
implicated in the activation of p53 protein, such as phosphorylations, 
dephosphorylations, acetylations, and binding to certain proteins (for review see Meek 
1994; Chernov et al., 1998). Both posttranslational modifications and alternations in 
p53 binding proteins appear to be major contributors to the modulation of p53 activity. 
Carboxy terminal phosphorylation and incubation with a Carboxy terminal binding anti-
p53 antibody markedly enhanced sequence-specific DNA binding of p53 (Hupp et al., 
1993). This evidence showed that Carboxy terminus domain of p53 is the regulatory 
region of the protein.  Mdm2 protein as a major intracellular regulator of ubiquitin-
mediated degradation of p53 protein (Haupt et al., 1997; Kubbutat et al., 1997). Mdm2 
protein can inhibit p53 function by binding to and inhibiting transactivation by p53. 
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The existence of these various regions of p53 provides a way by which a 
primary p53 regulatory mechanism could be by specific post-translational modifications 
or one or more of these domains, or modulation of proteins that bind to these domains. 
The cell uses different functions and proteins to recognize different classes of DNA 
damage and different systems of enzymes to repair them. For example, ATM kinase 
activity is enhanced following ionizing radiation (IR) and this protein is shown to 
phosphorylate Serine-15 of p53. ATM was also implicated in a radiation-induced 
dephosphorylation event. IR causes a loss of a phosphate group from Serine 376 in the 
carboxy terminus of p53 in an ATM dependent manner and this dephosphorylation 
event results in a creation of a binding for 14-3-3 proteins and enhancement of 
sequence-specific DNA binding (Waterman et al., 1998) (Table 1.1).  
 
Figure 1.3: Summary of posttranscriptional modifications and domains of p53. (From Giaccia 
&Kastan,  1998).  
 
Ultra violet (UV) irradiation is also a potent inducer of p53 protein; however, 
clear differences exist in p53 induction following UV radiation versus IR. UV signaling 
to p53 does not depend on ATM kinase but lysine residues in the N terminal domain of 
p53 are acetylated by PCAF and p300/CBP (Lill et al., 1997; for review see Giaccia & 
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Kastan 1998) (Figure 1.3) . In addition to DNA damage, hypoxia is able to stimulate 
p53 levels and activate p53 protein in a different way from UV radiation and IR. It was 
suggested that hypoxia increases p53 protein levels via induction of another protein, 
HIF-1β ( An et al., 1998). 
Yet a third signal to activate p53 is sent when ribonucleoside triphosphate pools 
fall below a critical threshold. Normal nucleoside triphosphate pools are necessary to 
support DNA replication and progression through the cell cycle (Linke et al., 1996).  As 
seen in the examples, activation of p53 is complex and tightly regulated process. 
Table 1.1 Representative examples of proteins interacting with p53. 
 
PROTEIN CATEGORY / FUNCTION REFERENCE 
SV40Tag viral (Lane et al., 1979)  
HPV E6 viral (Scheffner et al., 1992) 
Ad E1b-55 viral (Kao et al., 1990) 
EBV EBNA-5 viral (Szekely et al., 1993) 
TBP Transcription Factor/ Part of TFIID (Seto et al., 1992) 
TAFII60,TAFII
40 
Transcription Factor/ Part of TFIID (Thut et al., 1995) 
RPA Replication (Dutta et al., 1993) 
Mdm2 oncoprotein / inhibitor of p53 (Momand et al., 1992) 
WT1 transcriptional activator / tumor 
suppressor  
(Maheswaran et al., 1993) 
Sp1 transcriptional activator (Gualberto et al., 1995) 
CK2 protein kinase (Meek et al., 1990) 
DNA-PK protein kinase (Lees-Miller et al., 1990) 
ATM protein kinase (Banin et al., 1998) 
p300/CBP histone acetylase (Lill et al., 1997) 
E6-AP ubiquitin system protein (Huibregtse et al., 1993) 
HMG1 DNA bending (Jayaraman et al., 1998) 
p19ARF tumor suppressor (Kamijo et al., 1998) 
p33ING1 tumor suppressor? modulator of p53 (Garkavtsev et al., 1998) 
RAD51 replication/repair (Buchhop et al., 1997) 
REF1 redox/repair (Jayaraman et al., 1997) 
BRCA1 tumor suppressor/repair (Zhang et al., 1998) 
ERCC2 helicase / Part of TFIIH (Xiao et al., 1994) 
XPD helicase/ Part of TFIIH (Xiao et al., 1994) 
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1.2.5 Downstream Events 
The transcriptional activating function of p53 is a major component of its 
biological effects. By binding to specific sites within their promoters, p53 activates the 
transcription of various genes including, p21WAF1, GADD45, mdm2, bax, 
thrombospondin 1, cyclin G, and insulin-like growth factor binding protein 3 (IGF-
BP3) (Figure1.4) (for review see Somasundaram & El-Deiry 2000). 
The p53-dependent G1 arrest occurs largely through the transactivation of 
p21WAF11 (el-Deiry et al., 1993). p21WAF1  is a member of small cyclin-dependent kinase 
inhibitor (CKI) family. It binds to a number of cyclin and cyclin-dependent kinase (cdk) 
complexes, by this way inhibits the transition to S-phase. p21WAF1 also binds to 
proliferating cell nuclear antigen (PCNA), and inhibits the role of PCNA as a DNA 
polymerase processivity factor in DNA replication (Waga et al., 1994).  
More recently, p53 has been implicated in a G2/M phase checkpoint. When 
mitotic spindle inhibitors are added to cells with wild-type p53, the cells are blocked in 
G2. In the absence of wild-type p53, these cells reinitiate DNA synthesis. These data 
suggest that p53 may be part of a G2/M checkpoint, preventing premature entry into 
another S phase. In addition p53 appears to be an integral part of the process that 
regulates the number of centrosomes in a cell (Cross et al.,1995; Fukasawa et al., 
1996).  
Another way for eliminating abnormal cells is apoptosis. p53 mediates apoptosis 
in several cell types in response to several stimuli, including DNA damage, adenovirus 
E1A expression, myc expression or withdrawal of growth factors. p53 may use 
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transcriptional activation or direct protein signaling (protein-protein interactions) (Hupp 
et al., 1995) or both to initiate apoptosis. 
 
 
Figure 1.4 Major downstream targets of p53 ( From Somasundaram & El-Deiry 2000). 
 
Two of the genes that are regulated by p53 could influence the decision to 
commit to an apoptotic pathway: bax and IGF-BP3 (Miyashita and Reed, 1995; 
Buckbinder et al., 1995). Bax is a tumor suppressor gene whose protein product 
interacts with bcl-2 protein. Bcl-2 is an anti-apoptotic factor and increased bax 
expression block the functioning of this protein. A second p53 regulated gene product 
that could affect growth regulation is the IGF-BP3. IGF-BP3 protein blocks the IGF 
mitotic signaling pathway by binding to IGF and preventing its interaction with its 
receptor. Thus, the blocking of IGF activity could enhance apoptosis or lower the 
mitogenic response of cells.  
Number of factors, like extend of DNA damage, certain oncogenic disruptions, 
availability of survival or growth factors, and cell type, affect the decision of a cell to 
enter a p53-mediated cell cycle arrest or apoptotic pathway.  
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1.2.6 The p53 Family 
For a long time, p53 was thought to be alone, but two mammalian proteins, p73 
and p63, with significant sequence homology to p53 have recently been identified. Its 
first relative, TP73, which encodes p73, was identified by chance in 1997 (Kaghad et 
al., 1997), and its second, TP63 (which encodes p63 and is also known as KET, P51, 
P40, chronic ulcerative stomatitis protein (CUSP) and P73L), was identified 
independently by several groups (Yang et al., 1998; Trink et al., 1998; Osada et al., 
1998; Augustin et al., 1998; Senoo et al., 1998; Lee et al., 1999). There are several 
common features among the p53 gene family members. (1) They all contain very large 
introns, (2) exon1 is always non-coding, (3) the exon/intron organization of all the 
family members is highly similar (Figure 1.5).   
Both p63 and p73 give rise to many differently spliced mRNAs, which are 
translated into several different proteins. Most of the splicing occurs at the 3’ end and 
creates proteins that have different C-termini. There are at least six alternatively spliced 
forms of human p73: p73α, p73β, p73γ, p73δ, p73ξ, p73ε (Kaghad et al., 1997; De 
Laurenzi et al., 1998) in addition to these COOH-termini splice forms, two additional 
forms, ∆Np73α, and ∆Np73β, result form the use of an alternative promoter located in 
intron 3 (Yang et al., 1998). The TP73 gene contains 14 exons and is located at 
chromosome 1p36.33. The TP63 gene is located at chromosome 3q27-29 and contains 
15 exons (Yang et al., 1998; Osada et al., 1998) and can be transcribed from two 
different promoters, which are located upstream of exon1 and within intron 3 (Yang et 
al., 1998). Recognized variants of TP63 include the α, β, and γ forms of p63. 
Furthermore p63 utilizes a cryptic promoter located in intron 3 to generate additional 
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transcripts called ∆Np63α, ∆Np63β, ∆Np63γ (Figure 1.5). The three members of the 
p53 family share very significant homology both at the genomic and at the protein 
level. Each contains a transcriptional activation domain (TAD), a DNA-binding domain 
(DBD) and an oligomerization domain (OD). In addition p63 and p73, but not p53, 
contain long C-termini (for review see Levrero et al., 2000). 
 
Figure 1.5: Exon-intron organization of p53 family members, showing different transcripts. 
 
The highest level of homology is reached in the DBD (63% identity between 
p53 and p73, and 60% identity between p53 and p63), which suggests that the three 
proteins can bind to the same DNA sequences and transactivate the same promoters. 
The vast majority of missense mutations of p53 found in human tumors are clustered in 
the sequence specific DNA-binding domain. In addition, p73 and p63 are 29% and 22% 
identical to the region corresponding to the N-terminus transactivation domain of p53 
respectively. Residues in the C-terminus region of p73 and p63 are 38% and 37% 
identical to the corresponding C-terminus oligomerization domain of p53 (for review 
see Chen 1999). The nuclear import and nuclear export signals lie within the 
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oligomerization domain and are conserved among p53 from different species as well as 
in p63 and p73. The sequences of p63 and p73 diverge from p53 mostly in their C-
termini. Furthermore different p63 and p73 C-termini are generated as a result of 
alternative mRNA splicing. The determination of the three dimensional solution 
structure of the p73 C-terminus has shown that this region contains a sterile alpha motif 
(SAM), which is a protein-protein interaction domain (Chi et al., 1999). The SAM 
domain is a globular domain composed of four α-helices and a small 310-helix. SAM 
domains are protein-protein interaction modules found in proteins involved in 
developmental regulation. This domain is also present in p63 C terminus. Although 
SAM domains are known to participate in homotypic or heterotypic interactions, the 
p73 and p63 domains bind neither to themselves nor to each other. Nevertheless, it is 
possible that these domains interact either with a distantly related SAM domain protein 
or perhaps with a non-SAM containing protein (Figure 1.6) ( for review see Irvin & 
Kaelin 2001; Kaelin 1999). 
 
Figure 1.6: Homology between the p53 family members. AD, activation domain, PXXP proline rich 
repression domain, Oligo, oligomerization domain, Basic, C-terminal basic domain ( from Chen, 1999). 
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p73 was initially proposed as a possible tumor suppressor gene because it is 
related to p53, it maps to chromosome 1p36.33, a region frequently deleted in 
neuroblastoma and other human cancers and it has been found to be monoallelically 
expressed owing to genomic imprinting (Kaghad et al., 1997). However the status of 
p73 as a tumor suppressor gene has been challenged by recent observations. It was 
found that p73 can be biallelically expressed in both normal or tumor tissues and cell 
lines, including neuroblastoma and mutation of the p73 gene occurs infrequently in 
human cancers (Ichimiya et al., 1999; Han et al., 1999). 
It is not also certain whether p63 is a tumor suppressor gene. p63 is located at 
chromosome 3q27-29, a region that is not a common site of loss of heterozygosity in 
human cancers. p63 gene was found to be mutated infrequently in both human tumor 
tissues and cancer cell lines (Osada et al., 1998). Although p63 might have functions 
similar to those of p53 in cell-cycle arrest and apoptosis, ∆Np63, which lacks an 
activation domain, inhibits the activity of both p53 and p63, thereby exhibiting 
oncogenic functions (Yang et al., 1998).  
While p53 is ubiquitously expressed, p73 and p63 are restricted to certain 
tissues. In the developing mice, p73 is detected in the epidermis, sinuses, inner ear, and 
brain while p63 is expressed in proliferating basal cells of the epidermis, cervix and 
prostate. In the p63- deficient mice, the apical ectodermal ridge essential to limb 
development is defective, and the mice have truncated limbs. In addition, p63 knockout 
mice have no hair follicles, no teeth, no mammary, lachrymal or salivary glands (Mills 
et al., 1999; Yang et al., 1999). Thus the phenotype of p63-deficient mice suggests that 
the primary biological function of p63 proteins is to regulate development. Recently 
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mutations of p63 have been detected in children affected by ectrodactyly ectodermal 
dysplasia and facial clefts (Celli et al., 1999). Ectodermal dysplasia is manifested by 
changes in skin, hair, nails, teethlacrimal duct, and urogenital tract. Similar to p63-
deficient mice, p73-deficient mice exhibit severe defects, including hydrocephalus, 
hippocampal dysgenesis, chronic infections and inflammation, and abnormalities in the 
pheromone sensory pathway. However they do not develop any spontaneous tumors 
(Yang et al., 2000). According to these findings, both p63 and p73 play very important 
roles in ectodermal differentiation and neurogenesis respectively. However these 
findings do not exclude the roles of p63 and p73 as tumor suppressors. Therefore the 
functions of p53 family may overlap in some tissues because of the requirement for 
simultaneous activity of p53, p63 and p73 at specific stages of development. 
Although there is a high degree of sequence similarity between p53 and p73, 
neither SV40 TAg, E1B55k, nor E6 oncoproteins bind to p73 (Marin et al., 1998; 
Higashino et al., 1998; Roth et al., 1998). However the possibility exists that they can 
be bound and inactivated by other viral proteins. Only one viral oncoprotein, adenovirus 
E4orf6, was capable of associating with p73 and inhibiting the activity of p73 in one 
experimental protocol (Steegenga et al., 1999), but not in another (Roth et al., 1998). 
Thus further studies are required to address this issue. Whether these viral oncoproteins 
can regulate p63 remains to be determined.  
Like p53, p73 and p63 can induce cell-cycle arrest and apoptosis (Kaghad et al., 
1997; Yang et al., 1998; Osada et al., 1998; Jost et al., 1997; Zhu et al., 1998). Loss of 
p73 transcriptional activity abrogates its activity in cell-cycle arrest and apoptosis 
(Kaghad et al., 1997; Jost et al., 1997; Zhu et al., 1998). It is known that p53 
upregulates p21WAF1, an inhibitor of cyclin-dependent kinases.  Both p63 and p73 also 
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can induce p21WAF1 transcription. Although p73 can induce p21WAF1, the level of 
cellular p21WAF1 induced by p73 is several times lower than that induced by p53. Two 
other p53 targets GADD45 and B-cell translocation gene 2 antiproliferative are only 
weakly activated by p73.  
Like p53, p73 can induce G2/M arrest, p73 is capable of inducing 14-3-3σ (Zhu 
et al., 1998). However, p73 induces several fold higher levels of 14-3-3σ gene product 
than does p53.  It remains to be found whether p63 can induce 14-3-3σ and cell-cycle 
arrest at G2/M. 
Although both p53 and p73 can induce apoptosis (Jost et al., 1997; Zhu et al., 
1998), the signaling pathways may be different because of the different abilities of p73 
to activate some p53 target genes. While bax and several redox-related genes (PIG2, 
PIG3, PIG6 and PIG11) are possibly involved in mediating p53-dependent apoptosis 
(Miyashita et al., 1994; Polyak et al., 1997),  they were not significantly induced by p73 
(Zhu et al., 1998). Because p73 transcriptional activity is required for inducing 
apoptosis (Jost et al., 1997; Zhu et al., 1998),  it is possible that p73 can activate a 
different subset of cellular genes for mediating apoptosis.  
Mdm2, an oncogene that negatively regulates p53, and is also induced by p53 
(Wu et al., 1993), is weakly induced by p73β and p73α. The interaction with Mdm2 
leads to the inactivation of transcription and apoptosis functions of p73-β and p73-α 
(Zeng et al., 1999) but does not result in the rapid degradation of p73 protein (Zeng et 
al., 1999; Dobbelstein et al., 1999).  Disruption of Mdm2-p73 interaction is needed for 
stimulation of transcription and apoptosis by p73 but does not effect the stability of p73. 
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Accumulation of p73 in response to certain DNA-damaging stimuli relies on the 
activity of the c-Abl tyrosine kinase, which prolongs the half-life of p73 (Gong et al., 
1999). The accumulation of p53 and p73 in response to certain stimuli occurs through 
independent pathways. The accumulation of p53 is regulated by the inhibition of its 
degradation, but the accumulation of p73 requires the activity of the stabilizing protein 
(c-Abl) ( Yuan et al., 1999; for review see Levrero et al.,2000).  
Although ultraviolet light, actinomycin D, and methylmethane  sulfonate 
(MMS) do not induce the accumulation of p73, cisplatin, which crosslinks DNA (Gong 
et al., 1999), and taxol, an agent that stabilizes microtubules and prevents completion of 
mitosis, induce p73 accumulation and increase its half-life. Later it was shown that 
cisplatin and ionizing irradiation could regulate p73 through protein accumulation or 
tyrosine phosphorylation, respectively (Gong et al., 1999; Agami et al., 1999; Yuan et 
al., 1999). These post-translational modifications of p73 occur through its physical 
interaction with c-Abl kinase. According to these findings, regulation of p73 in 
response to several types of DNA damage is a complex phenomenon that may be 
mediated by the recruitment of the different upstream proteins.     
1.3 ING1 Gene and its Protein product p33 
A novel gene called “Inhibitor of Growth 1, ING1” encoding a 33 kDa protein 
was identified by subtractive hybridization (Garkavstev et al., 1996) (see Appendix A 
for more info.).  By using indirect immunofluorescence, it is shown that the p33ING1 
protein is located in the nucleus, with its proposed role as a growth regulator. Also a 
genomic probe to human ING1 localized to chromosome 13 at q33 → q34 by 
fluorescence in situ hybridization (ISH). This area is close to known sites of genomic 
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alteration in several human cancers: primary gastric cancer, haematologic neoplasms, 
and head and neck squamous cell carcinomas (Zeremski et al., 1997).  
All the initial studies of ING1 protein was done by using p33ING1, but later the 
authors reported that the constructs used in these studies were actually the p24ING1, one 
of the three products of human ING1 gene, due to a cloning defect (Garkavstev et al., 
1999) (see detailes later).  
First studies showed that, p33ING1 (p24ING1), the protein product of ING1 gene, 
regulate the growth negatively. Overexpression of transfected ING1 constructs 
efficiently decreased S-phase fraction by blocking the entry of cells into S-phase. 
Chronic expression of antisense constructs resulted in tumor induction in vivo and in 
foci formation and ability to grow in soft agar in vitro. Further studies suggested that 
p33ING1  may be involved in cell cycle control like many other tumor suppressor genes. 
Consistent with it playing a growth inhibitory role, the RNA and protein levels of 
ING1(p24ING1) increased eight- to ten-fold in senescent cells compared to young 
proliferation-competent human diploid fibroblasts. Additionally, chronic expression of 
antisense ING1 (p24ING1) RNA resulted in extension of the proliferative life span of 
normal human diploid fibroblasts (Garkavstev et al., 1997a).  
The ING1 gene also appears to be involved in the modulation of some cellular 
forms of apoptosis including the developmentally programmed certain multipotent 
embryonic cells. Overexpression of the p33ING1 (p24ING1) protein conferred sensitivity 
to apoptosis in different cell models, whereas decreasing ING1 (p24ING1) expression 
using an antisense construct protected cells from apoptosis. These properties of p33ING1 
(p24ING1) are very similar to some tumor suppressor genes, such as p53. Also it was 
shown that, in response to UV exposure that causes DNA damage, p33ING1b translocates 
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to the nucleolus. Two stretches of four amino acids act as a nucleolar targeting 
sequence and mutants of the nucleolar targeting sequence are less effective in inducing 
apoptosis in primary human diploid fibroblasts (Scott et al., 2001). Another study 
reported that p33ING1, is induced at both mRNA and protein levels in melonama cell line 
after UV irradiation and p33ING1 protein enhances nucleotide excision repair of both 
UV-damaged genomic DNA and exogenous plasmid DNA supporting that p33ING1 is a 
tumor suppressor (Cheung et al., 2001). 
ING1 gene products contain a zinc finger motif. Zinc finger motifs comprise 
several structural subfamilies and most of them are thought to participate in recognition 
of macromolecules, such as DNA, RNA and protein. The carboxyl-terminal 70 amino 
acid residues of ING1 contain the Cys4-His-Cys3 sequence of a Plant Homeo Domain 
(PHD) finger domain. PHD finger domains have been found in many different proteins, 
including transcription factors and other proteins implicated in chromatin mediated 
transcriptional regulation (Aasland et al., 1995). 
A p33ING1 homolog was identified by a search of a database of randomly 
sequenced human cDNAs (see appendix B for details). The new gene was called as 
ING1L (for ING1-like protein). The full-length ING1L cDNA contained an open 
reading frame of 840bp, encoding a deduced protein of 280 amino acids with a 
predicted molecular weight of 32.8kDa. ING1L gene is mapped to 4q35.1 by ISH and 
radiation hybrid mapping techniques. Comparison of the deduced amino acid sequence 
of ING1L with p33ING1, the gene products showed 58.9% identity. A PHD-type zinc 
finger motif was present in the carboxyl terminal halves of both ING1L and p33ING1. 
Northern blot analyses revealed that ING1L is ubiquitously expressed in various human 
22
 
tissues and there is a relative increase in the mRNA levels of ING1L in colon cancer 
tissues compared to normal counterparts (Shimada et al., 1998).  
Association of ING1 gene products with growth suppression, replicative 
senescence, anchorage dependence, and apoptosis raised the question of its relationship 
with p53. In 1998, Garkavtsev and his collogues reported that p33ING1 (p24ING1) directly 
cooperates with p53 in growth regulation by modulating the ability of p53 to act as a 
transcriptional activator. Reduction of ING1 (p24ING1) expression inhibits the growth 
suppressive activity of p53, suggesting that p33ING1 (p24ING1) is essential for p53 
function. The mechanism of the cooperation between p33ING1 (p24ING1) and p53 
involves physical interaction between these two proteins, which form a complex 
detectable by immunoprecipitation. Furthermore, it was shown that activation of 
transcription from the p21WAF1 promoter, a key mechanism of p53 mediated control, 
depends on the expression of p33ING1 (p24ING1) (Garkavstev et al., 1998). These data 
place p33ING1 into a family of p53-interacting proteins, including Mdm2, Ref-1 and 
p300 which modulate p53 activity through physical interaction. The involvement of 
p33ING1 (p24ing1) in this signaling pathway indicates that ING1 may be a potential tumor 
suppressor gene, the loss or inactivation of which may contribute to alter cell growth 
control, resistance to apoptosis or establishment of the immortal phenotype in tumors 
retaining wild type p53.   
1.3.1 Structure of ING1 gene 
In 1999, Zeremski and his collaborators reported the detailed structural and 
expression studies of mouse ortholog of the human ING1, ing1, gene. Mouse homolog 
of ING1, ing1, is transcribed from at least three differently regulated promoters, and 
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resulting transcripts encode at least two different proteins. All of the transcripts share a 
common region encoded by a common exon but differ in their 5’-exons. Two of the 
three alternative exons do not contain protein-coding sequences, while the third one 
does. Therefore one of the ing1 transcripts encodes a 37-kDa protein (p37ING1), while 
two others are translated into a shorter protein 24 kDa that surprisingly runs as if it was 
31 kDa (p31 ING1). p37ING1 is ubiquitously expressed in thymus, spleen, liver, lung, 
brain, heart, and testis in mouse but p31 ING1 levels vary among organs and cells. There 
is a link between the proliferation rate of the cell and ing1 expression both at the protein 
and mRNA levels. The most important and interesting finding of this work is the two 
products of ing1 have opposite effects on p53-dependent transcription regulation; one, 
p31ING1, acts as a p53 cooperator, while the other, p37ING1,  acts as a p53 suppressor. 
p53 is found in a complex with the long but not with the short product of ing1 and 
overexpression of the longer product inhibits accumulation of p53 protein after DNA 
damage. This may show a new genetic mechanism of promoting cancer that involves an 
imbalance between the two products of one gene. Overexpression of the longer product 
of ING1 could be the mechanism of attenuation of p53 activity in tumors that do not 
require mutations in p53 itself (Zeremski et al., 1999).   
Alignment of the predicted amino acid sequences with that of human p33ING1 
revealed 89% similarity between the mouse and human proteins (Zeremski et al., 1999).  
Human ING1 gene has three exons, from which four mRNA variants are 
transcribed from three different promoter regions (Figure 1.7) (Gunduz et al., 2000; 
Cheung & Li 2001). 
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Figure 1.7: Genomic structure of human ING1 and its alternatively spliced mRNA variants. 
p47ING1, p32ING1, p27ING1, and p24ING1 .(■) Coding sequence in exon. (□) Noncoding sequence 
in exon. 
 
1.3.2 ING1 Gene products in chromatin remodeling complexes 
Recently, the functions of three yeast proteins Yng1, Yng2, and Pho23, which 
have strong sequence identity in their C-termini PHD finger domains with the human 
ING1 gene, have been investigated. These three yeast proteins have a role in chromatin 
remodeling and transcriptional regulation. Yng2 associates with Tra1, a yeast homolog 
of TRRAP, which associates with PCAF histone acetyl transferase (HAT) complex. 
TRRAP was identified as a cofactor that interacts with c-Myc and E2F-1 and is required 
for transformation by c-Myc and E1A (McMahon et al., 1998). It has also been shown 
that Yng1, Yng2 and Pho23 are complexed with HAT activities. HAT activities are 
often found in large, modular, multiprotein complexes containing known transcriptional 
regulators. Yng1, Yng2, and Pho23 associate with HAT activities with preferences for 
different histones, suggesting that they associated with different HAT complexes. The 
homology between these yeast proteins and p33ING1 (p24ING1) suggests that these 
proteins are functionally related. ING1 also associates with HAT activity when it is 
expressed in yeast. The structure and function of ING1 and Yng2 particularly well 
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conserved suggesting that human ING1 may be associated with HAT activity and 
TRRAP, the mammalian homolog of Tra1, in mammals (Loewith et al., 2000). A model 
in which ING1 regulates HAT activity would be consistent with its putative tumor-
suppressor role. 
Another study showed that alternative transcripts of human p33ING1 
differentially associate with mSin3 transcriptional corepressor complex and have 
HDAC1-dependent transcriptional corepressor activity in reporter gene assays. While 
p33ING1b is associated with the Sin3/HDAC1 mediated transcriptional repression, 
p24ING1c does not seem to interact with the Sin3/HDAC1 complexes (Skowyra et 
al.,2000). These findings suggest that this interaction is through N-terminal region of 
p33ING1 protein because the three alternative transcripts vary in their N-terminal region.  
1.3.3 Cancer Development and p33 
ING1 gene emerged as a candidate tumor suppressor gene because: 1) it is 
located on 13q, a frequent deletion target in many tumor types, including head and neck 
cancer; 2) it was found to be genetically altered in one neuroblastoma cell line, and 
decreased rates of protein expression have been detected in several breast cancer cell 
lines; 3) it interacts with the p53 protein in vitro; and 4) the biological effects of the 
p33ING1 and p53 proteins may be interrelated, since the ING1 gene is implicated in p53 
mediated cell growth inhibition. For these reasons scientists started to investigate 
p33ING1 mutations, deletions and rearrangements in different cancer type ( for review 
see; Cheung & Li 2001). 
Recently, it has been reported that the ING1 gene is mutated very rarely in 
primary breast and ovarian cancers and breast cancer cell lines. Also expression of 
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ING1 gene is reduced in high proportion of breast tumors (44%) and in all breast cancer 
cell lines. Furthermore it has been suggested that ING1 expression levels correlate 
strongly with metastasis, with tumors showing reduced levels of ING1 being metastatic 
at a frequency at least six fold greater than these showing increased levels of ING1 
(Garkavstev et al., 1999). 
However molecular analysis of the ING1 in human head and neck tumors with 
13q deletions, showed no somatic mutation in any of the tumors or cell lines (Sanchez-
Cespedes et al., 1999). Recently another study suggested that of 34 informative cases of 
head and neck squamous cell carcinoma, 68% of tumors showed loss of heterozygosity 
at chromosome 13q33-34, where the ING1 gene is located. Three missense mutations 
and three silent changes were detected in the ING1 gene in some tumors with allelic 
loss at the 13q33-34 region. These missense mutations were found within the PHD 
finger domain and nuclear localization motif in ING1 protein. These changes may 
effect the PHD finger and break the three-dimensional structure of ING1 protein 
leading, the loss of the function (Gunduz et al., 2000). In 31 informative esophageal 
squamous cell cancer cases, nearly 60% of tumors showed allelic loss at chromosome 
13q33-34 and four tumor specific missense mutations detected within the PHD-finger 
domain and nucleolar localization motif of the ING1 (Chen et al., 2001).  
The p33ING1 status in colorectal carcinomas showed that allelic deletion of, or 
mutations within, the ING1 gene do not appear to occur during colorectal 
carcinogenesis ( Sarela et al., 1999). 
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1.4 Aim and Scope of the Project 
From the evidences presented above, it is obvious that understanding the 
signaling pathways of p53 family proteins and the proteins involved in these pathways 
is crucial to solve the cancer puzzle.  
 This study aims at the identification of the interacting domain of p53 family 
proteins with p33ING1 protein. For this purpose, mapping of the interacting regions of 
p53 family proteins with p33ING1 protein has been investigated, by using in vitro 
methods namely GST pulldown and Far Western Blotting. For this purpose different 
deletion mutants of p53 family proteins were created and cloned into expression vectors 
and used in vitro protein-protein interaction assays. 
 Such a study is thought to highlight the significant points in the interactions 
among mentioned proteins.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Chemicals 
The laboratory chemicals were analytical grade and supplied from Sigma 
Biosciences Chemical Company Ltd. (St. Louis, MO, U.S.A) or from Carlo-Erba 
(Milano, Italy). 
2.1.2 Bacterial Strains 
The bacterial strain used in this work had the following genotypes: 
E. coli, DH5α: F-, (f80dÊ(lacZ)M15), recA1, endA1, gyrA96, thi1,hsdR17,(r-km-k), 
supE44,relA1, deoR, Ê(lacZYA-ar gF)U169 
2.1.3 Enzymes 
Restriction endonucleases were purchased either from MBI FERMENTAS Inc. 
(NY, U.S.A) ( SalI, XbaI, XhoI , BamHI, NotI, ApaI, EcoRI, NheI, KpnI) or from 
Appligene-Oncor (Illkirch, France) (HindIII, SacI). Cloned Pfu Polymesase was 
purchased from Stratagene (CA, U.S.A). T4 Ligase was purchased from MBI 
FERMENTAS Inc. (NY, U.S.A).  
2.1.4 Oligonucleotides 
The oligonucleotide primers used for the PCR amplification of p33ING1,p63, p73 
and for C-terminal deleted forms of these genes were synthesized in the Beckman Oligo 
1000M DNA synthesizer (Beckman Instruments Inc. CA. U.S.A) at the Bilkent 
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University, Faculty of Science, Department of Molecular Biology and Genetics, 
(Ankara, Turkey).  
The primers for p33 are: 
Forward: 5’- AGACGTCGACAAATGTTGAGTCCTGCCAACG -3’ 
SalI 
 
Reverse: 5’- AGACAAGCTTCTACCTGTTGTAAGCCTCTC -3’ 
HindIII 
 
Reverse: 5’-ATATAAGCTTATTAGGGGACGAATCTCGCTC-3’ 
HindIII 
 
The primers for p63 are: 
 
Forward: 5’-GATAGGATCCATGTCCCAGAGCACACAG-3’ 
BamHI 
 
Reverse: 5’-CGCGCTCGAGTCACTTTGTACTGTCCGAAAC-3’ 
XhoI 
The primers for p73 are: 
 
Forward: 5’-TATAGGATCCATGGCCCAGTCCACCGCC-3’ 
BamHI 
 
Reverse: 5’-CGCGCTCGAGTCACTTGGCGGAGCTCTCGTT-3’ 
XhoI 
 
Prior to synthesis, the primers were optimized for their annealing temperature, 
%GC content, hairpin and dimer formation potential with the help of Primer Designer 
Version 2.0 computer program (Scientific & Educational Software,1990,1991). It was 
confirmed by the Clone Manager Version 4.0 computer program (Scientific & 
Educational Software) that p33ING1 cDNA contained no apparent SalI, HindIII, KpnI 
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and EcoRV restriction enzyme recognition sequences, p63 cDNA and p73 cDNA 
contained no apparent BamHI and XhoI restriction enzyme recognition sequences . 
2.1.5 Cloning Vectors 
PGEM-T Easy is a convenient vector for the cloning of PCR products. This 
type of vectors have 3’-terminal thymidine at both ends. These single 3’ overhangs at 
the insertion site greatly improve the efficiency of ligation of a PCR product into a 
plasmids by preventing recircularization of the vector and providing a compatible 
overhang for PCR products generated by certain thermostable polymerases, like Taq 
DNA Polymerase (Figure 2.1).   
 
Figure 2.1 Vector map of pGEMT-easy 
 
pBluescript II KS- (GenBank #X52326) is a phagemid that permits expression 
of cloned genes in bacterial systems or in vitro transcription-translation (IVTT) 
reactions in eukaryotic systems. The vector contains T3 and T7 viral promoters that 
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span the multiple cloning site and are oppositely oriented. These promoters enable 
eukaroytic expression of the cloned gene in the presence of respective viral RNA 
poymerases (Figure 2.2).  
 
 
Figure 2.2: Vector Map of pBlueScript II KS- 
 
pcDNA 3   is a mammalian expression vector. The vector contains both T7 and 
Sp6 viral promoters, spanning the multiple cloning site. These promoters and CMV 
promoter permits the expression of this plasmid both IVTT reactions and mammalian 
systems respectively (Figure 2.3). 
2.1.6 Antibodies 
The primary antibodies used in GST pulldown assays are as follows: 
monoclonal anti p33 antibodies (3G6, 20H6, 15B9, 9H9),  produced by Rengül Çetin-
Atalay, monoclonal mouse-anti-p53 antibodies (7D3: specific to amino acids 211-220 ; 
T7 ↓ 
NotI 
XbaI 
BamHI 
SmaI 
EcoRI 
HindIII 
SalI 
XhoI 
ApaI 
DraII 
KpnI 
T3↑ 
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HR221: specific to amino acids 371-380; 9E4 specific to amino acids 281-290) kindly 
provided by Dr. Esma Yolcu (Yolcu et al.,2001). 
 
Figure 2.3: Vector Map of pcDNA3 
 
 
2.1.7 Commercially Available Kits 
QIAquick PCR Purification Kit (by Qiagen (Chatsworth, CA, U.S.A)) is used 
for cleaning nucleic acids from contaminants. 
QIAEXII (by Qiagen (Chatsworth, CA, U.S.A)) is for extraction of DNA bands 
from agarose gels. 
QIAGEN Plasmid Purification Kit (by Qiagen (Chatsworth, CA, U.S.A)) is 
utilized to obtain plasmid DNA at higher amounts and concentrations with higher purity 
than those achieved by MiniPrep. 
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pGEM-T and pGEM-T Easy Vector Systems is purchased from Promega 
(Madison, WI, USA) for the easy cloning of the genes in vectors.  
 TNT Coupled Reticulocyte Lysate System is purchased from Promega (Madison, 
WI, USA) for the single step in vitro transcription-translation (IVTT) of the cloned 
genes in an eukaryotic system. 
Amplify Solution from Amersham (Uppsala, Sweden) is a flourimetric method 
to enhance the visualization of the signals generated by radioisotopes on 
polyacrylamide gels. 
2.1.8 Apparatus 
Vertical mini gel apparatus for polyacrylamide gel electrophoresis and the 
power supply are products of E-C Apparatus Corp. (Florida, U.S.A). Horizontal midi 
gel apparatus used for agarose gel electrophoresis is purchased from Stratagene. 
Thermal cycler for PCR is a product of Perkin Elmer (CA, USA). Slab Gel Dryer is 
from Savant Instruments Inc.(N.Y.,USA). Semi-dry transfer unit for Far Western 
Blotting and GelDoc2000 Image analyzer for agarose gels are purchased from Bio Rad 
Laboratories (CA, U.S.A). 
2.1.9 Materials for Autoradiograghy 
Radiolabelled methionine (35S-Methionine) and light-proof film cassette 
(Hypercassette) and film developing unit are products of Amersham (Uppsala, 
Sweden). Medical X-ray films are purchased from Fuji (Tokyo, Japan).  
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2.1.10 DNA and Protein Size Markers 
As a DNA size marker, 1 kb DNA Ladder from MBI FERMENTAS Inc. (NY, 
U.S.A) is used.SDS-PAGE protein size markers are either from Pharmacia (Uppsala, 
Sweden) or Bio Rad Laboratories (CA, U.S.A) (prestained markers).  
2.2 Solutions and Media 
2.2.1 Agarose Gel Electrophoresis Solutions 
Tris-acetic acid-EDTA (TAE) 40mM Tris-acetate    
      1mM EDTA 
 
Ethidium bromide:   10 mg/ml in water (stock solution), 
      30 ng/ml (working solution) 
 
1x Gel loading buffer:        0.25% bromophenol blue, 0.25% xylene  
     cyanol, 50% glycerol, 1mM EDTA 
 
2.2.2 Solutions for Plasmid DNA Isolation (MiniPrep) 
Solution I    50 mM Glucose, 25 mM, Tris.Cl, pH 8.0,  
     10M EDTA. Sterilize in autoclave. 
Solution II    0.2 N NaOH, 1% (wt/vol) SDS 
Solution III    3 M Potassium acetate, pH 4.8  
     11.5% (v/v) glacial acetic acid 
Phenol/ Chloroform   100% equilibrated phenol / 100% chloroform 
2.2.3 Solutions for Bacterial Transformation 
CaCl2     50 mM in double distilled water,  
     filter sterilized. 
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Transformation Buffer 10 mM PIPES, 55 mM MnCl2, 15 mM CaCl2, 250 
mM KCl, Filter Sterilized and stored and 4˚C. 
2.2.4 Microbiological media and antibiotics 
Luria-Bertani medium (LB)  Per liter: 10 g nutrient broth, 5 g bacto- 
     yeast extract, 8 g NaCl, 0.52g Tris Base 
     For LB-agar plates, add 15 g/L bacto agar. 
     Sterilized by autoclave. 
 
SOB Per liter: 2% tryptone, 0.5% yeast extract, 10 mM 
NaCl, 2.5 mM KCl, Autoclaved to sterilize. Then 
20 mM MgSO4 and 10 mM MgCl2. 
 
SOC Per liter: SOB + 20 mM Glucose from filter 
sterilized 1 M Glucose stock solution in ddH2O. 
 
DMSO     Commercially available, 100% 
 
Ampicillin    working solution: 100 µg/ml or 50 µg/ml 
stock solution :100 mg/ml in ddH2O  
 (stored at -20°C) 
2.2.5 Polyacrylamide Gel Electrophoresis Solutions 
Resolving (Lower) Buffer (2X) 375mM TrisHCl, 0.2% SDS, pH 8.9 
 
Stacking (Upper) Buffer (2X):  250mM TrisHCl, 0.2% SDS, pH6.8 
 
Running Buffer (1X)   25mM Tris base, 192 mM glycine, 1% SDS 
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Sample Dye (2X)      50mM TrisHCl pH6.8, 1% SDS, 2mM EDTA, 1% 
2-ME, 0.02% Bromophenol Blue,10%  glycerol 
Acrylamide-Bisacrylamide mix 24% acrylamide, 0.64% bisacrylamide (stock) 
 
Amonium persulphate (APS)  10% (w/v) ammonium persulphate in  ddH2O                                
 
Coomassie Staining Solution  Solution1: 10% Acetic Acid 
Solution2: 0.04% Coomassie G Blue, 0.5% 
CuSO4  in 27% ethanol 
Mix Solution1 and 2 at a ratio of 1:1 
 
Destain Solution   14% ethanol, 7% acetic acid in ddH2O 
2.2.6 Far Western Buffers 
Denaturation Buffer:   Hepes (pH:7.8)           25mM 
                                           NaCl                          25mM 
                                           MgCl2                          5mM  
                                           GnHCl                          6M 
                                           DTT                             1mM 
 
Renaturation Buffer:    Hepes (pH:7.8)           25mM 
                                           NaCl                          25mM 
                                           MgCl2                          5mM  
                                           GnHCl                         0.187M 
                                           DTT                            1mM 
 
Saturation Buffer:        Hepes (pH:7.8)           25mM 
                                           NaCl                          25mM 
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                                           MgCl2                          5mM  
                                           DTT                            1mM 
                                           NP-40                         0.05% 
                                           Milk Powder                    1% 
 
IVTT Buffer:                 NaCl                                0.1M 
                                           Tris HCl (pH: 7.6)           20mM 
                                           DTT                                 1mM 
                                           EDTA                              1mM 
                                           Glycerol                           10% 
                                           Milk Powder                       1%     
 
2.2.7 Solutions for Trichloroacetic acid Precipitation 
TCA Solution:        Trichloroacetic acid             5% (w/v)                         
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2.3 Methods 
2.3.1 PCR amplification of cDNA 
PCRs were performed using Cloned Pfu DNA Polymerase from Stratagene (La 
Jolla, CA, U.S.A) as described in the manual provided by the supplier with some 
modifications. Ingredients of each 50 µl reaction is as follows: Cloned Pfu DNA 
Polymerase (2.5 units), dNTP mix from MBI FERMENTAS Inc. (NY, U.S.A) (10 
nmoles), buffer of Cloned Pfu DNA Polymerase (1x), specific forward and reverse 
primers (250 ng or 125 ng each), DNA template ( 6µl from MCF7 total cDNA, or 1 µl 
from pBks plasmid containing the genes of interest), ddH20 (making the total volume 
50µl). Care was taken not to contaminate the reaction tubes with foreign DNA. Every 
time, a negative control reaction that contains no DNA template was set up. High 
extension times (2.5 min/cycle) were applied to compensate the low nucleotide 
incorporation rate of the enzyme. Polymerase was added into the reaction tubes after the 
initial denaturing step to disallow premature extention (“Hot Start PCR”). PCR products 
are checked for length and purity by AGE.  
2.3.2 Agarose gel electrophoresis of DNA 
DNA fragments were fractionated by horizontal electrophoresis by using 
standard buffers and solutions. DNA fragments less than 1 kb were generally separated 
on 1.0 % agarose gel, those greater than 1 kb were separated on 0.8 % agarose gels. 
Agarose gels were completely dissolved in 1x TAE electrophoresis buffer to 
required percentage in microwave and ethidium bromide was added to final 
concentration of 30 ng/ml. The DNA samples were mixed with one volume-loading 
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buffer and loaded onto gels. The gel was run at room temperature in 1x TAE at 
different voltage and time depending on the size of the fragments. 
Nucleic acids were visualized under ultraviolet light (long wave, 340 nm) and 
standard DNA size marker, 1 kb DNA ladder, was used to estimate the fragment sizes. 
2.3.3 Recovery of DNA Fragments from Agarose Gels 
DNA fragments were extracted from agarose gels by using the QIAEX II gel 
extraction kit according to the manufacturer’s instructions. 
Gel purification with the QIAEX II kit yields 60-70 % recovery of DNA 
fragments between 1.0 kb to 6.0 kb in 10-20 µl volume. 
2.3.4 Methods for Cloning and Subcloning of Genes 
2.3.4.1 PolyA Extension Reaction 
Gel-extracted PCR products were polyA extended using Taq DNA Polymerase 
enzyme. Ingredients of polyA extension reaction are as follows: Taq DNA Polymerase 
(1µl), dATP (2mM dATP/µl), Taq DNA Polymerase Buffer (1x), DNA extracted from 
gel (7 µl). Reaction tubes were incubated at 70οC during 30 minutes.  
2.3.4.2 Insertion of Products of PolyA Extention Reaction into pGEM-T easy 
vector 
Insertion of products of PolyA extention reaction were performed in 15 µl 
insertion reaction volume for overnight incubation at 16°C. Reactions were carried out 
with the appropriate reaction buffer and according to the manufacture’s 
recommendations.   
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2.3.4.3 Restriction Enzyme Digestion of DNA 
Restriction enzyme digestions were routinely performed in 20 µl reaction 
volume for 1.5 to 4 hours and typically 1-10 µg DNA and 5-15 units of restriction 
enzyme was used. Reactions were carried out with the appropriate reaction buffer and 
conditions according to manufacturer’s recommendations. 
Digestion of DNA with two different restriction enzymes simultaneously was 
generally possible by using a universal buffer (potassium acetate buffer) that fulfills the 
activity requirements of both enzymes. In this regard, Y+/Tango Buffer from MBI 
Fermestas was usually suitable. The working concentration of this buffer was modified 
for each enzyme (either 1x or 2x), and this way, it was possible to match the buffer 
requirements of various enzymes simultaneously.  
2.3.4.4 DNA Ligation Reactions 
DNA fragments were ligated into plasmid vectors in 15 µl reaction volumes 
containing 0.3-1.0 µg of linearized plasmid vector and 7-10 times molar excess of insert 
DNA in the presence of 1-4 Weiss units of T4 ligase and 1x concentration of the 
standard ligation buffer supplied by with the enzyme. The reaction mix was incubated 
at either room temperature for 2.5-4 hours or at 16oC overnight.  
2.3.4.5 Transformation of E.coli 
Transformation of plasmid DNA into E.coli was achieved by using calcium 
chloride method. The following procedure is based on Ausubel et al. (1991). 
 
 
41
 
Preparation of competent cells 
This method is based on a report by Inoue et al. 1990. DH5α cells were grown 
in SOB medium at 30oC to an A600 of 0.5-0.6 with vigorous shaking/stirring at 200 rpm 
and cooled down on ice for 10 minutes. Cells were transferred to 500 ml centrifuge 
bottles and centrifuged at 300 rpm (Beckman JA10 rotor, pre-cooled at 4oC). The pellet 
was resuspended in 1/3 of the initial volume of ice-cold transformation buffer by gently 
swirling and kept on ice for 10 minutes. The suspension was then centrifuged at 3,000 
rpm for 10 minutes. The pellet was gently resuspended in 1/12.5 initial volume of ice-
cold transformation buffer and DMSO was added while gently swirling to a final 
concentration of 7 %. Before distribution into tubes, incubation was done on ice for 10 
minutes. Tubes were immersed in liquid nitrogen to freeze rapidly and stored at –80oC.  
Transformation 
Competent cells from –80oC stock were thawed at room temperature and placed 
on ice as soon as completely thawed. 200 µl of cells were dispensed into plastic tubes 
(15 ml tubes). DNA to be transformed up to 20 µl was added and incubated on ice for 
30 minutes. After heat-shock at 42oC for 30 seconds, tubes were put on ice and 800 µl 
SOC was added. Following incubation at 37oC with vigorous shaking for 1 hour, cells 
were plated out on LB+ selective agent(s). 
2.3.4.6 Plasmid DNA Preparation 
Small scale isolation of plasmid DNA  (MiniPrep) 
The transformant bacteria strain containing the plasmid of interest was grown in 
5 ml LB medium containing 100 µg/ml ampicillin at 37°C, while shaking at 200 rpm 
overnight. 1.5 ml culture was pelleted in 1.5 ml microfuge at 13,000 rpm for 2 min. 
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After removal of supernatant, the cells were resuspended in 100 µl ice-cold Solution I. 
Freshly prepared 200 µl of Solution II was added and mixed in by inverting the tube 
very gently. Bacterial chromosomal DNA and cell debris were precipitated by the 
addition of  150 µl of Solution III. Then, 500µl of Phenol/Chloroform was added. The  
tubes were vortexed vigorously for 2 min and centrifuged for 5 min at 13,000 rpm, 4°C 
to pellet the host DNA and proteins. Supernatant was transferred into a new eppendorf 
tube, mixed with 1 ml ice-cold absolute ethanol and the mixture was incubated at -80°C 
for 20 min. The plasmid was recovered by centrifugation at 13,000 rpm for 25 min at 
4oC.  The pellet was washed with 300 µl 70% ethanol. Ethanol was aspirated and the 
pellet was air-dried. The pellet was resuspended in 20-30 µl sterile distilled H2O 
containing 10 µg/ml RNase A and incubated at 37°C for 10-20 minutes and 
resuspended. The sample was kept at 4°C for short-term or at -20°C for long-term 
storage. This procedure yields approximately 1-1.5 µg of DNA per reaction. 
Purification of plasmid DNA using the Qiagen Kit (MidiPrep) 
The Qiagen 100 kit was used for large scale isolation of pure plasmid DNA. The 
method is based on the “midi-prep” instructions supplied with the QIAGEN Plasmid 
Midi Kit (Cat. No. 12145) by Qiagen (Germany). 
This procedure yields approximately 60-150 µg of plasmid DNA from 100 ml 
of initial bacterial culture. 
2.3.5 Quantification of Nucleic Acids 
Concentrations and purity of the double stranded nucleic acids (plasmid DNAs 
and constructs) and oligonucleotides were determined by using the Beckman 
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Instruments Du Series 600 Spectrophotometer software programs (ds DNA and Oligo 
DNA Short methods) on the Beckman Spectrophotometer Du 640 (Beckman 
Instruments Inc. CA. U.S.A) at A260 and A280. 
2.3.6 Growth and Storage of Bacterial Strains 
A single bacterial colony picked from either an agar plate or a loopfull of 
bacterial glycerol stock was inoculated into 5 ml LB (containing the appropiate 
antibiotics, if necessary) in 15 ml screw capped tubes. The tubes were incubated at 200 
rpm at 37°C overnight in a rotator-incubator. 
Bacterial strains were stored in 2 ml cryotubes at -80°C in LB medium 
containing 40% glycerol for long term storage. Recombinant clones were stored under 
the same condition in media containing the appropriate antibiotic. Strains were 
maintained as isolated colonies on LB agar plates at 4°C for short term storage. 
2.3.7 SDS Polyacrylamide Gel Electrophoresis 
Electrophoretic separation of proteins under denaturing conditions was 
performed by following the methods described in Sambrook et. al. (1989) with slight 
modifications. 8%, 10%, 12% gels were made according to the specific purpose. The 
mini gel glass plates were assembled according to the manufacturer’s instructions (E-C 
Apparatus Corp). In order to prepare a 12% gel, 5 ml of 2x resolving gel, 5 ml of 
acrylamide-bisacrylamide mix, 140 µl of 10% APS, 8 µl of TEMED were mixed and 
poured into the gap between the glass plates. Sufficient space (the length of the comb 
teeth plus 1 cm) was left for the stacking gel. Water saturated 2-propanol was layered 
onto the top of the gel. After the gel was settled and polymerized at room temperature, 
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the 2-isopropanol layer was removed and 3% stacking gel (3ml 2x stacking buffer, 0.75 
ml acrylamide-bisacrylamide mix, 2.25 ml double distilled water, 100 µl 10% APS, 6 µl 
TEMED) was poured on top of the resolving gel. The comb was immediately inserted 
into the stacking gel, being careful to avoid air bubbles. After the gel was polymerized, 
the comb was removed and the wells were cleaned from  the remaining unpolymerized 
gel  by a syringe. 2x sample buffer was added to the samples and the samples were 
heated for 5 min at 95oC, when necessary prior to loading. After loading the samples to 
the wells, the gel was mounted in the electrophoresis tank and 1x SDS-running buffer 
was added to the top and bottom reservoirs. The gel was run such that each gel received 
around 25 mA of current. The gel was then either fixed and amplified or used in semi-
dry tranfer. The gels were dried in slab gel dryer for long term storage 
2.3.8 In vitro Transcription-Translation (IVTT) Reactions 
TNT Coupled Reticulocyte Lysate  System from Promega Corp. (WI,USA) 
provides a conventional system for protein synthesis. Transcription and translation from 
an open reading frame cloned in a vector having either T7 or T3 viral promoters are 
facilitated as a single, coupled reaction. All the transcription and translation machinery 
is supplied by the reticulocyte lysate of rabbit. In addition to its ease and rapidness, this 
system provides a means to label the protein of interest. Labeling takes the form of 
radio-labeling, such that exogenously supplied methionine which contains a radioactive 
sulfur (35S-Methionine) is incorporated into the polypeptide of interest during 
translation. Radio-labeled proteins can be further used in various experiments, such as 
GST Pulldown assays.  
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IVTT was performed as described in the  manual supplied by the manufacturer. 
Care was taken to prevent RNase contamination by using filtered micropippette tips, 
DEPC ddH2O, and RNasin (RNase inhibitor from Promega Corp.) when available. 
Always a negative control lacking the DNA template was used to check foreign DNA 
contamination. At the end of the reaction, protease inhibitor cocktail was added into 
each reaction mix to a final concentration of 1X and kept a 4oC for short term (1-2 
days) storage.  pBluescript II KS- and pcDNA3 were used as the cloning vectors from 
which IVTT reactions took place. 
Measuring of Incorporated S-Methionine 
The incorporated 35S-Methionine was measured after IVTT reaction before 
using in Far Western and GST pulldown assays. 2µl from each IVTT reaction product 
was put on  two sets of the glass fiber filters and dried. The first set of  these filters were 
air dried only. The second set of these filters were incubated in 5% TCA solution during 
5 minutes, and boiled in TCA solution during 5 minutes. After boiling, the filters were 
air-dried and both sets were measured using Liquid Scintillation Counter. 
2.3.9 GST Pulldown Assays 
GST Pulldown Assays were employed to detect the in vitro interaction between 
p33ING1 and p53 family proteins and to map the interacting region on p53 family 
members with p33ING1. In this system, a GST-fusion protein is bound to gluthatione-
sepharose beads. The next step is to incubate this complex with the labeled polypeptide 
whose interaction with the GST-fusion protein is investigated. Following extensive 
washes; the reaction mixture is subjected to SDS-PAGE. If an interaction between the 
polypeptides is present, the labeled protein persists in the reaction mixture despite 
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washes, and it can be detected because of its label. Label of the second protein is in the 
form of radioactivity due to 35S-labeled methionine that is incorporated into the protein 
during IVTT reaction. In this study, different radiolabeled deletion mutants of p53 
protein family and p33ING1 were synthesized in vitro in order to detect the regions of 
p53 family proteins required to interact with p33ING1. 
 The assay was performed as follows: Gluthatione-Sepharose beads (25  µl per 
reaction) were equilibrated by washing with binding buffer (25 mM HEPES pH 7.5, 
10% glycerol,150 mM KCl, 0.1% NP40) twice. Centrifugation of beads between 
washes and all through the process was for 4 min at 2000 rpm. Beads were resuspended 
in 25  µl of binding buffer per reaction and GST-fusion proteins were added. For each 
GST pulldown assay, 3 reaction were set: one with purified GST-p33 ( 4 µg) which was 
the test sample; one with purified GST (2 µg) which was a negative control; one with 
no protein at all which was another negative control. These samples were incubated 
with the beads overnight at 4oC, on a shaker. Then, reaction mixes were saturated with 
BSA (final concentration: 3%) for 2 hrs at 4oC, on a shaker, and washed with 1 ml of 
binding buffer for 3 times. 25  µl of buffer per reaction was left in the tube at the last 
wash. Following saturation, 10  µl of  the second protein (radiolabeled IVTT reaction 
product) plus DTT (final concentration: 1mM) were added to the reaction mix and 
incubated for 2 hrs at 4oC, on a shaker. Washes were performed at 4oC with wash buffer 
(20 mM TrisHCl pH7.5, 200 mM KCl, 1% NP40). Each sample was washed with 1 ml 
of buffer for 4 times. Microcentrifuge tubes of the reaction mixes were changed after 
first wash in order to prevent false positives in case radioactivity adsorbs to the tube. 
After the washes, bead pellets were resuspended in SDS-loading dye (25  µl) and 
47
 
incubated in boiling water for 5 min to disrupt all protein-protein interactions, followed 
by brief centrifugation to pellet the beads. The supernatants were subjected to SDS-
PAGE, and then the polyacrylamide gels were incubated in fixing solution (25% 2-
propanol, 10% acetic acid) for 30 min at RT and incubated in Amplify solution to 
enhance radioactivity intensity for 20-30 min at RT. Gels were then dried in vacuum 
dryer and exposed to X-ray films overnight to 48  hrs. 
2.3.10 Far Western Blotting 
Far Western Blotting is a novel technique to show protein-protein interaction in 
vitro (Guichet et al., 1997). By the help of this technique, interacting regions of the 
proteins can also be detected. In this system, protein of interest is first run on SDS-
PAGE and then transferred to the nitrocellulose membrane like usual Western Blotting. 
Then this membrane is first denaturated, then renaturated and saturated with different 
buffers and finally incubated with a radioactively-labeled IVTT product. Following 
several times washing, membrane is exposed to X-ray films. If there is an interaction, 
interacting protein is held on the membrane and can be detected by autoradiography. 
The assay was performed as follows: 10µg from GST-p33, GST and purified 
6Histidine-PTEN protein run on 10% SDS-PAGE and then transferred to the 
nitrocellulose membrane by applying 12V, during 1 hour. After transfer, proteins on the 
membrane is first denaturated at 4oC, 30 minutes in denaturation buffer and then 
renaturated at 4oC, during 1 hour, in renaturation buffer and then membrane was 
saturated in saturation buffer 2 hours at 4oC. During these processes, wild type p53, 
p63, p73 proteins and their C-terminally deleted forms were in vitro transcribed-
translated and radioactively labeled, each in 25µl reaction volume, by IVTT reaction. 
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The incorporated radioactivity were measured using liquid scintillation counter for each 
sample, and equal amounts of the IVTT products were incubated with nitrocellulose 
filters in IVTT saturation buffer. Following overnight incubation at 4οC, the membrane 
was washed twice with IVTT saturation buffer and was exposed to X-ray films for 3-7 
days. 
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CHAPTER 3: RESULTS 
 
Former studies carried out in our laboratory, revealed that the possible 
interacting region of p53 with p33ING1 is at the C-terminus of the protein by GST 
pulldown assays (Emre N. C. T., 1999). Therefore in the first part of our studies, the 
interacting region of p53 and p33ING1 was confirmed by in vitro protein-protein 
interaction assays. For the ultimate mapping of the region of p53 interacting with 
p33ING1; new deletion mutants of p53 were cloned and used in GST pulldown and Far 
Western assays. The second task of our study was to look for whether the members of 
the same family also interact with p33ING1 gene product, or not. Full-length p63 and p73 
proteins were shown to interact with p33ING1 by Far Western Blotting. Then C-
terminally deleted forms p63 and p73 were amplified and cloned into expression 
vectors and checked for the interaction with p33ING1 by in vitro protein-protein 
interaction assays.  
3.1 Examination of Deletion Mutant Constructs of p53 
Previous studies in our laboratory have examined the interacting region of p53 
protein with p33ING1 by using different deletion mutants of p53 in vitro analysis. These 
studies showed that the interacting region of p53 is at the C-terminus of the protein. The 
results of these studies are summarized in Table 1(Emre N. C. T., 1999). 
The first part of our studies concentrated on the confirmation of the former 
results by GST pulldown assays. Before producing the wt p53 protein and its deletion 
mutants by the coupled in vitro transcription-translation reaction, all old p53 deletion 
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mutant constructs were checked for the presence of the desired inserts by single 
digesting with HindIII and double digesting with HindIII and SacI. Agarose gel 
electrophoresis of the digestion reaction products was shown in Figure 3.1, all with the 
expected inserts.  
 
 
Table 3.1: Different deletion products of p53 and their interaction status with p33ING1  
Transcritional activation domain locates between aa residues 1-43, proline rich domain locates between 
aa residues 62-91, DNA binding domain locates between aa residues 102-292, oligomerization domain 
locates between aa residues 320-360, C-terminus domain locates between aa residues 330-393. 
 
 
 
 
 
The full-length human p53 protein and its deletion mutants, as presented in 
Table 1, were produced by the coupled in vitro transcription-translation kit of Promega 
(see Section 2.3.8) 
51
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Restriction enzyme digestion analysis of MiniPreps of deletion mutant constructs: : s: 
single digestion with HindIII; d: double digestion with HindIII/SacI 1:WT (1179 bp); 2:FaRu (1062 bp); 
3: F5R5 (1104 bp); 4; F4R3 (585 bp); 5:F2R2 (1014 bp); 6:F6R5 (1008 bp); 7: F4R4 (921 bp). 1% 
agarose gel. 
 
Figure 3.2 reveals that there has been protein synthesis from all of the 
constructs prepared. Some of the lanes contain 2 or more bands, which may be 
degradation products or premature translation-stop products. 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: SDS-PAGE analysis of IVTT reactions of deletion mutant constructs of p53:  
1: wtp53 (393 aa); 2:FuRz (361 aa); 3:F4R4 (307 aa); 4F6R5 (336 aa); 5:F2R2 (338 aa); 6:F4R3 (195 
aa); 7:FaRu (354 aa); 8:F5R5 (368 aa); 9:NC. IVTT reaction was performed in 25µl reaction volume for 
each sample. 12% SDS-PAGE. 
 
3.2 Confirmation of Previously Obtained Results 
 GST pulldown assays were used in order to map the regions of p53 that interact 
with p33ING1. For each GST pulldown assay, 3 reactions were set: one with purified 
3000 bp 
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GST-p33ING1 which was the test sample; one with purified GST, which was a negative 
control; one with no protein at all which was the other negative control. 
Initially, before testing the p53 deletion mutants for mapping purposes, the full-
length p53 was shown to bind GST- p33ING1, but not either to GST or the gluthatione 
beads, in vitro by GST pulldown assays.   
 
 
 
                                                                                                                                                                     
 
Figure 3.3: GST pulldown assay of wt p53 with GSTp33.   
N: no protein (-) control; G: with GST protein (-) control; P: with GST-p33 protein. 12% SDS-PAGE. 
 
In Figure 3.3, there are several bands in the last lane, which may be degradation 
products or premature translation-stop products. After verifying the in vitro interaction 
of the full-length proteins (see Figure 3.3), p53 deletion mutant constructs were tested 
for the confirmation and initial mapping of the p53’s interacting region. Eight different 
constructs (including the wt p53), together with their negative controls, were first in 
vitro transcribed and translated and then used in GST pulldown assays.  
The results of this experiment confirmed the previous findings. Figure 3.4 
shows that the interacting region(s) is at the C-terminus region of the p53 protein. The 
interaction in tubes containing N-terminus mutant forms of p53, F2R2 and FaRu, was 
not inhibited. However when the C-terminus of the p53 was deleted the interaction was 
inhibited. 
 
N   G       P 
46  kD 
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Figure 3.4: GST pulldown with p53 deletion constructs.   
 N:  no protein; G: with GST protein; P: with GST-p33 protein. 12% SDS-PAGE.   
 
 
 
F6R5       del. 300-357 
    N     G       P 
F2R2       del. 44-99 
      N     G       P 
F4R3       del. 98-293 
    N      G        P 
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   N      G       P 
F5R5       del. 300-325 
   N      G       P 
FuRz       del. 363-393 
 N     G       P 
F4R4       del. 207-293 
    N     G       P 
   wt p53         
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 To examine this interaction more precisely, GST pulldown assays were 
repeated by using different p53 and p33ING1 antibodies.  
3.3 Specific Monoclonal Antibodies to p53 and p33ING1 can not Inhibit the 
Interaction 
Another way to find out the interacting region of p53 with p33ING1 was to use 
the monoclonal antibodies against p53 and p33ING1 in conjunction with GST pulldown 
assays. If the IVTT-p53 (wt) and GST-p33ING1 incubated with a monoclonal antibody, 
reacted with a site that was required for the interaction of these proteins, we would 
expect a decrease or loss of GST-p33ING1-p53 binding compared to control reaction 
without the antibody.  
The GST pulldown assays with antibodies specific to p53, including the C-
terminus specific p53 antibody, HR231, and specific to p33ING1 were performed as 
described with the following modifications: just before incubating the IVTT reaction 
mixture with the bead-bound proteins, the IVTT of wt p53 was incubated with the one 
of the anti-p53 antibodies or one of the anti- p33ING1 antibodies were incubated with 
bead bound GST-p33ING1 protein. p53 and p33ING1 antibodies were available as 
hybridoma supernatants, 8µl from each hybridoma supernatant was added to each 
reaction mixture and incubated for 30 minutes at 30°C. As a control, one reaction with 
no antibody was also performed in parallel (supplemented with regular DMEM instead 
of hybridoma supernatant). Figure 3.5 shows that the intensity of the signal with the 
antibodies does not change significantly when compared to control (no antibody) 
reaction. The C-terminus specific antibody HR231 also could not inhibit the interaction 
between these two proteins.The interaction between these two proteins is either too 
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strong to be inhibited by antibodies or the antibodies in hand are not specific to the 
region which is directly involved in interaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: GST pulldown assay with p53 and p33ING1 antibodies 7D3: specific to aa 211-220; 
HR231: specific to aa 371-380; 9E4: specific to aa 281-290; specificities of p33ING1 antibodies does not 
known yet; N:  no protein; G: with GST protein; P: with GST-p33ING1 protein. 12% SDS-PAGE. 
 
3.4 Demonstration of p53 and p33ING1 Interaction by Far Western Analysis 
As previously mentioned, Far Western assay was used to find out and confirm 
the interacting regions between p53 and p33ING1  Far Western blotting was a method of 
choice because of its specificity.   
Prior to testing the interaction of the proteins, the Far Western assay was 
optimized using full-length p53. This assay was tried in two different ways: First 
without the inclusion of the denaturation and renaturation steps and secondly with the 
inclusion of the buffers by applying the radioactively labeled in vitro synthesized wt 
p53 directly onto the saturated membrane. The results, Figure 3.6, showed that 
denaturation and renaturation steps are vital for this assay, since the interaction between 
labeled p53 and GST-p33ING1 could only be seen with treated membrane. 
 
      with  p53 antibodies                   with p33ING1 antibodies 
      7D3     HR231     9E4                3G6     20H6         15B9      9H9 
wt p53 
N    G       P 
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Figure 3.6: Optimization of Far Western assay. N: GST protein only (-) control; P: GST p33ING1 
protein. 10µg protein was loaded in each lane. First gel was not treated with denaturation/renaturation 
buffers, second gel was treated with denaturation/renaturation buffers.  
 
After optimization of the conditions and showing that wt p53 interacts with 
GSTp33ING1, this experiment was repeated by using the C-terminus deleted mutant of 
p53, FuRz, which does not have the last 30 amino acids of the wild type p53. For this 
reason, wt p53 and FuRz were IVTT-produced and incubated with a nitrocellulose 
membrane containing denaturated/renaturated GST, GST- p33ING1 proteins.   
    
 
 
 
 
 
 
                                 (a)                                                                       (b)   
Figure 3.7: Far Western analysis of wt p53 and C-terminally deleted mutant of p53.  
(a): 3µl from each IVTT reaction product were loaded on 12% SDS-Polyacrlyamide gel as a positive 
control. 1:wtp53; 2: FuRz (missing last 30 amino acids from wt p53); N: IVTT reaction without template 
DNA (negative control). (b) 1: GST protein only (-) control; 2: GSTp33ING1 protein.   
 
 To ensure that both proteins were produced in IVTT reaction, 3µl from each 
reaction mixture were loaded an SDS-PAGE gel, fixed, amplified, dried and exposed. 
1 2 N
wtp53              FuRz ( del 361-393) 
1    2                 1    2 
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 Results of these experiments are showed in Figure 3.7. Although there is no 
interaction between p53 and GST protein (negative control), there is an interaction 
between GST-p33ING1-p53 and this interaction cannot be seen between C-terminally 
deleted form of p53 and p33ING1.  
3.5 Subcloning of p53 cDNA and p53 Deletion Mutant Constructs 
 In order to determine exactly which regions of p53 protein interact with p33ING1, 
new C-terminally deleted constructs of p53 protein were used and cloned into a vector, 
such as pBks, which permits IVTT reaction. In one of these constructs, F6R6, only the 
oligomerization domain was deleted, and in the other construct, FuR6, both 
oligomerization domain and rest of the C-terminus region of the p53 protein were 
deleted.  
 The subcloning experiments were performed as follows. As a starting material, 
E. coli glycerol stocks of the constructs were available. One of these constructs, F6R6, 
was chosen for the construction of the desired mutant p53 proteins. In this construct, the 
oligomerization domain of p53 was deleted, starting from 331aa to 357aa. All 
constructs had been ligated into the pAUCT/CCW vector directionally through NheI (5’ 
of the construct) and HindIII (3’ of the construct) restriction enzyme sites by Erden 
Gökay. Although pBks had a HindIII recognition site at its multiple cloning site it did 
not have an NheI site. Another restriction enzyme, XbaI, creates a compatible DNA 
overhang with NheI at its target sequence. XbaI recognition site was present in the 
multiple cloning sites of pBks and this enzyme was used to digest pBks along with 
HindIII.  The orientation of the DNA insert in pBks, when ligated at the mentioned 
restriction enzyme sites, enabled IVTT with the help of T7 viral RNA polymerase. 
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A different deletion-mutant of p53 was also prepared to better analyze the 
interacting regions of p53. In this new construct, named FuR6, a bigger deletion was 
done including the oligomerization domain and rest of the C-terminal region of the p53 
gene, starting from aa 331 to the end of the gene. To be able to prepare this mutant 
construct, F6R6 found in pAUCT/CCW was digested with NheI and XhoI, which make 
deletion at the desired parts and pBks vector was digested with XbaI and XhoI. 
 Following the AGE of the digestion products, desired DNA bands were 
extracted from the agarose gel. Ligation reactions were set up between purified vector 
and insert sequences as already mentioned. After transformation, positive colonies were 
chosen from the plates. Overnight-grown colonies were used for MiniPrep plasmid 
isolation. Those MiniPreps were subjected to restriction enzyme analysis. In order to 
perform double digest of the constructs, NotI and ApaI for F6R6-pBks construct and 
NotI and XhoI for FuR6 construct restriction enzymes were used. NheI-XbaI hybrid site  
 
 
  
 
 
 
 
Figure 3.8: AGE analysis of MiniPrep of pBksF6R6 and pBksFuR6 constructs.  
2µl of construct MiniPrep from chosen colonies was digested simultaneously with NotI and XbaI or NotI 
and XhoI (10 U each) in the presence of 2X of Y+/Tango Buffer for 4 hours at 35.5 C. 10µl of the 
digestion mixtures were loaded on the gel.  M: marker; u: undigested; d: double digested. 1% AGE. 
 
3000 bp 
1000 bp 
F6R6                                              FuR6 
u    d    u     d    u    d    u    d          u   d    u   d     u    d     u   d     M 
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produces a recognition site for NotI restriction endonuclease. Positive colonies were 
chosen and MidiPreps were prepared. Restriction double digest of MiniPreps of the 
constructs, presented in Figure 3.8, show the presence of the desired cloned inserts. 
3.6 Further Detailed Mapping of the Interacting domain of p53 with p33ING1 by In 
Vitro Techniques 
 Newly subcloned C-terminus deletion constructs of p53 protein were used in 
GST-pulldown assays with their negative controls for the ultimate mapping of the p53’s 
interacting region. Before using in GST pulldown assay, the constructs were checked in 
IVTT reaction for the presence of the desired proteins. Two different p53 C-terminally 
deleted mutant constructs, F6R6 and FuR6, were used for further GST-pulldown 
analysis. In both of these constructs the oligomerization domain of the p53 was deleted 
but in FuR6 in addition to oligomerization domain the remaining C-terminus region of 
the protein was deleted.  
 
 
 
 
 
                                
                        (a)                                                              (b) 
Figure 3.9: GST pulldown with p53 deletion constructs. (a): 3µl from each IVTT reaction product 
were loaded on 12% SDS-Polyacrlyamide gel as a positive control. 1:wt p53; 2: F6R6 (del; 331-357); 3: 
FuR6 (del; 331-393); N: IVTT reaction without template DNA (negative control). (b) GST-pulldown 
assay of different p53 C-terminally deleted mutants; N: no protein (-) control; G: with GST protein (-) 
control; P: with GST- p33ING1 protein.  
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 The results, presented in Figure 3.9, showed that there is no nonspecific 
interaction either between beads and p53 or GST protein and p53. Radioactively labeled 
p53 protein specifically interacts with p33ING1 protein and this interaction is only seen  
 
when the oligomerization domain of the protein is intact. Both of the deletion mutant 
constructs of p53 failed to interact with p33ING1. Although FuR6 does not have the last 
62 amino acids of p53 protein, in F6R6 the only missing region is the oligomerization 
domain of the p53. This result suggests that the oligomerization domain is required in 
p53- p33ING1 interaction.  
 This result was confirmed by Far Western analysis of the same constructs. All 
the conditions were kept the same with the previous assays with the addition of another 
negative control. An unrelated protein, 6Histidine-PTEN, was loaded onto SDS-
Polyacrlyamide gel along with GST and GST-p33ING1. As a positive control 3µl from 
each IVTT reaction product was run on SDS-Polyacrylamide gel.  
  
 
 
 
 
 
 
 
Figure 3.10: Far Western with p53 deletion constructs. Nitrocellulose membranes containing 
6Histidine-PTEN , GST and GST-p33 proteins were incubated with indicated in vitro transcribed-
translated  p53 deletion mutant constructs.1: with  6Histidine-PTEN protein (as a negative control); 2: 
with GST protein (-) control; 3: with GST-p33 protein (test sample) 
  wt p53                                F6R6                           FuR6 
1    2     3                          1      2      3                 1        2       3 
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Result of Far Western analysis was confirmed the results of GST-pulldown assay. The 
interaction was possible only when full-length p53 and p33ING1 were present. 
3.7 Demonstration of Interaction between p33ING1 and other p53 Family Members  
 Among p53 family members, there are highly conserved functional domains. 
Oligomerization domain is one of these domains, which is at the C-terminus region. In 
addition p63 and p73, proteins have SAM domains at their C-termini, which may be 
involved in protein-protein interactions. In the light of these observations, we decided to 
make sequence analysis of the C-terminus region of the p53 family members. Based on 
the high homology between p63 and p73 to p53 sequences having a role in the 
interaction with p33ING1, the alignments were done with the deleted portions of p53 to 
see whether the deleted parts interfering with the interaction with p33ING1 are conserved 
in p63 and p73. Depending on this conservation, we tried to find any possible 
interaction between p63 and p73 with p33ING1 in vitro. Therefore, Far Western assay 
was repeated by using radioactively labeled IVTT products of wild type p63 and p73 
proteins. 
  
 
 
 
 
Figure 3.11: Far Western analysis of  wt p63 and wt p73.  (a): 3µl from each IVTT reaction product 
were loaded on 12% SDS-Polyacrlyamide gel as a positive control. N: IVTT reaction without template 
DNA (b) Far western analysis of wt p63 and wt p73 with GSTp33. (1): incubated with IVTT reaction 
product containing no DNA template; (2): incubated with IVTT reaction product containing wt p63 as a 
template; (3): incubated with IVTT reaction product containing wtp73 as a template. N: GST protein only 
as a negative control; P: GST p33ING1 protein (10µg from each protein was loaded on the SDS-
Polyacrlyamide).  
  N  p63  p73 
a b 
    1                2                  3 
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 After each IVTT reaction 3µl from each reaction product was loaded onto SDS-
PAGE gels as a positive control then used in the Far Western assays. Figure 3.11 (a), 
shows the IVTT reaction products of the full-length p63 and p73 proteins before adding 
to the membrane containing GST alone and GST- p33ING1 proteins.    
 The result of this experiment was not surprising. As the Figure 3.11 shows, 
there is an interaction between p33ING1 and the other members of the p53 family. Since 
the C-terminus portion of p53 is required for this interaction, and oligomerization 
domain is the only conserved region at this part of the family members, we 
hypothesized that oligomerization domain may directly be involved in these 
interactions. To test this hypothesis, we prepared deletion mutant constructs of p63 and 
p73 and test these mutant proteins in protein-protein interaction assays in vitro. 
3.8 Cloning of C-terminally deleted forms of  p63, and p73  
 The oligomerization domain of p63 resides residues between 355-404 and of 
p73 resides residues between 351-383. Therefore, specific primers, having BamHI and 
XhoI restriction enzyme sites, excluding the last 311 aa of p63 and last 316 aa of p73 
were designed.  
 As a preliminary step to the cloning, p63 and p73 C-terminally deleted cDNAs 
were PCR-amplified from the plasmids containing full-length p63 and p73 genes (p63 
in PRc/CMV, p73 in pcDNA3). Specific forward and reverse primers that contained 
BamHI and, XhoI for restriction enzyme sites were used in the PCR reaction. PCR 
reaction mix was prepared as described in Section 2.3.1. Cloned Pfu polymerase was 
preferred over Taq polymerase because of its high fidelity due to 3’-5’ proofreading 
mechanism.  
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 PCR products, showed in Figure 3.12, were extracted and purified from gel. 
Extracted DNAs were subjected to the Poly A extension reaction to add adenine 
residues and ligated into the pGEMT-easy vector. The re-ligation control reaction was 
set up to see whether a self-ligation of the vector without insert has taken place. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. AGE of p63∆C, p73∆C PCR-products. M: DNA size marker; 1: p63∆C ; 2: p73∆C; (all 
same conditions, 5µl/lane); 1∗: p63∆C; 2∗: p73∆C;  pcr products after purification (3µl/lane); (-): negative 
control that contains no DNA. 1% agarose gel.  
 
 Super-competent E.coli cells were transformed by the ligation product. Along 
with the ligation product, control transformations were performed: transformation by 
the religation control (negative control); and by no DNA at all (mock transformation, 
negative control). Positive colonies were chosen and small-scale plasmid isolation was 
performed. Chosen colonies were examined by restriction enzyme digestion analysis. 
Medium-scale plasmid isolation was done from the colonies containing the desired 
genes. As seen in Figures 3.13-3.14, cloned insert is present at the expected size, 
around 1000bp, after restriction enzyme double digest, implying that the cloning 
processes was successful. 
  1        2     (-)        M 
1031 bp  
500  bp 
   1∗         2∗   M 
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Figure 3.13: AGE analysis of MiniPrep of pGEMTp63∆C . 2µl of construct MiniPrep from chosen 
colonies were digested simultaneously with BamHI and XhoI (10 U each) in the presence of 2X of 
Y+/Tango Buffer for 4 hours at 35.5 C. 10µl of the digestion mixtures were loaded on the gel.  M: 
marker; u: undigested; d: double digested. 1% agarose gel. 
 
 
 
 
 
 
  
 
Figure 3.14: AGE analysis of MiniPrep of pGEMTp73∆C constructs. 2µl of construct MiniPrep from 
chosen colonies were digested simultaneously with BamHI and XhoI (10 U each) in the presence of 2X of 
Y+/Tango Buffer for 4 hours at 35.5 C. 10µl of the digestion mixtures were loaded on the gel.  M: 
marker; u: undigested; d: double digested. 1% agarose gel. 
 
3.9 Subcloning of  C-terminally deleted forms of  p63 and p73 
 In order to express mutant and wild-type p63 and p73 in mammalian cells, 
p63∆C and p73∆C were subcloned from pGEM-Teasy to pcDNA3 directly. MidiPreps 
of p63∆C, p73∆C and pcDNA3 were double-digested with BamHI and XhoI restriction 
enzymes. The DNA fragments were purified by gel-extraction and AGE analysis 
performed. Ligation reactions were set up using the indicated vectors and then ligation 
u d X M
3000 bp 
1031 bp 
u d u d u d M
3000 bp 
1031 bp 
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reaction mixture along with the indicated controls were transformed into super-
competent E. coli cells. Positive colonies on the ligation plates were chosen and 
MiniPreps were prepared and analyzed by restriction enzyme digestion. MidiPreps of 
the positive colonies were prepared.  
 As the Figure 3.15 showed both of the mutant proteins was subcloned 
successfully from pGEMT-easy to pcDNA3. Restriction enzyme double digest showed 
that both of the deletion mutant constructs are at the expected size, around 1000bp. 
 
 
 
                    
 
                                           (a)                                                                               (b)       
Figure 3.15: AGE analysis of MiniPrep of pcDNA3p63∆C (a) and pcDNA3p73∆C (b) constructs. 
2µl of construct MiniPrep from chosen colonies were digested simultaneously with BamHI and XhoI (10 
U each) in the presence of 2X of Y+/Tango Buffer for 4 hours at 35.5 C. 10µl of the digestion mixtures 
were loaded on the gel.  M: marker; u: undigested; d:: double digested. 1% agarose gel. 
 
3.10 Production of Radioactively Labeled Deletion Mutant p63∆C  
 After cloned and subcloned, the expression of the newly cloned deletion mutant 
p63∆C was checked by the coupled in vitro transcription-translation kit of Promega (see 
Section 2.3.10)                                                                                
As the Figure 3.16 shows, p63 deletion mutant, p63∆C, was produced, in vitro 
by IVTT reaction. The size of the protein is nearly half of the wild type p63 protein, as 
we expected.  
 Because our p63∆C could be expressed the next step is to examine the 
interaction between p63∆C and p33ING1 in vitro. 
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Figure 3.16: SDS-PAGE analysis of IVTT reactions of deletion mutant construct of p63 . 12% SDS-
PAGE. 
 
3.11 Examination of Interaction between p63∆C and p33ING1 in vitro   
 This interaction was first analyzed by Far Western assay. Far Western analysis 
was repeated for wild-type p63 and p63∆C. All the conditions were kept the same with 
the previous assays with the addition of another negative control. An unrelated protein, 
purified recombinant protein purified 6Histidine-PTEN, was loaded onto SDS-
Polyacrlyamide gel along with GST and GST-p33ING1. As a positive control 3µl from 
each IVTT reaction product was run on SDS-Polyacrylamide gel.  
 
 
 
 
 
Figure 3.17: Far Western Blotting with p63 deletion constructs. The nitrocellulose membranes 
containing indicated proteins were incubated with IVTT products of either p63 or p63∆C.1: with 
6Histidine-PTEN protein (as a negative control); 2: with GST protein (-) control; 3: with GST-p33 
protein (test sample).  
 
As the figure shows, wtp63 does not interact neither with GST alone or purified 
6Histidine-PTEN protein but the interaction between p63 and GST p33ING1 is obvious 
    p63 NCp63∆C M 
  87 kD 
  46 kD 
      wt p63                                p63∆C  
   1     2      3                         1       2       3 
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and this interaction was disrupted when the C-terminal portion of the protein containing 
the oligomerization domain was deleted. 
Both wt p63 and p63∆C were used in GST pulldown assay and result of this 
experiment confirmed what was found in Far Western assay.  
 
 
 
 
 
 
 
Figure 3.18: GST pulldown with p63 deletion constructs.  GST-pulldown assay of either wt p63 or 
p63∆C; 1: no protein (-) control; 2: with GST protein (-) control; 3: with GST- p33ING1 protein. 12% 
SDS-PAGE. 
  
3.12 Cloning and the Subcloning of the deletion mutant of p33ING1 
 After mapping the interacting regions of the p53 family proteins, we decided to 
examine which region of p33ING1 is actually involved in interaction with p53 family 
members. To answer this question, we cloned the C-terminus deletion construct of 
p33ING1. We deleted the region containing the PHD finger domain, which is important 
for chromatin-mediating interactions and transcriptional regulation. Also PHD finger 
motifs are thought to participate in the recognition of the macromolecules, such as 
DNA, RNA and proteins (Aasland 1995). Based on these findings, we examined the C-
terminus region of p33ING1 in interactions with p53 family. 
           p63∆C        
       1        2       3 
          wt p63        
    1        2        3 
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 As a preliminary step to the cloning, p33ING1 cDNA was PCR-amplified from 
the plasmid containing full-length p33ING1 gene (p33 in pBks). Specific forward and 
reverse primers that contained SalI and HindIII restriction enzyme sites were designed 
and used in PCR reaction. PCR reaction mix was prepared as described in Section 2.3.1. 
PCR conditions were kept the same with the previous cloning experiments.  
   
 
 
 
 
 
 
Figure 3.19: AGE of p33ING1∆C PCR-product. M: DNA size marker; 1: wt p33(positive control); 2: 
p33ING1∆C; (all same conditions, 5µl/lane); 1∗: p33∆C; pcr product after purification (3µl/lane); (-): 
negative control that contains no DNA. 1% agarose gels. 
            
 PCR product, shown in Figure 3.19, was purified by gel and extracted from 
gel. Extracted DNA was subjected to the Poly A extension reaction to add adenine 
residues and ligated into the pGEMT-easy vector. The re-ligation control reaction was 
set up to see if a self-ligation of the vector without insert has taken place. 
 Super-competent E.coli cells were transformed by the ligation product. Along 
with the ligation product, control transformations were performed: transformation by 
the religation control (negative control); by no DNA at all (mock transformation, 
negative control). Positive colonies were chosen and small-scale plasmid isolation was 
performed. Chosen colonies were examined by restriction enzyme digestion analysis. 
  1          2        (-)        M 
1031 bp 
 500  bp 
    1∗     M 
 500  bp 
1031 bp
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Medium-scale plasmid isolation was done from the colonies containing the desired 
genes. 
 As Figure 3.20 shows, the restriction enzyme double digest of the MiniPreps 
resulted in the cloned insert, which is at the expected size between 700-800 bp. 
 
 
 
 
 
Figure 3.20: AGE analysis of MiniPrep of pGEMT-p33ING1∆C constructs. 2µl of construct MiniPrep 
from chosen colonies were digested simultaneously with HindIII and SalI (10 U each) in the presence of 
2X of Y+/Tango Buffer for 4 hours at 35.5 C. 10µl of the digestion mixtures were loaded on the gel.  M: 
marker; u: undigested; d: double digested. 1% agarose gels. 
 
 In order to express mutant and wild-type p33ING1 in mammalian cells, 
p33ING1∆C was first subcloned from pGEM-Teasy vector to pBks expression vector and 
then pcDNA3 mammalian expression plasmid. MidiPrep of p33ING1∆C and pBks vector 
were double-digested with SalI and HindIII and the DNA fragments were purified by 
gel-extraction and AGE analysis performed. Ligation reactions were set up using the 
indicated vectors and then ligation reaction mixture along with the indicated controls 
were transformed into super-competent E. coli cells. Positive colonies on the ligation 
plates were chosen and MiniPreps were prepared and analyzed by restriction enzyme 
digestion. The results of these analyses are presented in Figure 3.21. MidiPreps of the 
positive colonies were prepared.  
At the end of this step, p33ING1∆C was in the pBks vector, therefore it is 
subcloned once more from pBks to pcDNA 3.  Also full-length p33ING1 was in the pBks 
   u     d      u       d      u      d       u     d      M  
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vector too. Both full-length p33ING1 and p33ING1∆C were subcloned from pBks to 
pcDNA3. p33ING1 and also pcDNA 3 were digested with KpnI and EcoRV and gel-
extracted. Ligation reaction were set up with the purified fragment and vector DNA 
along with the controls and incubated 16 hours at 16°C. 
 
 
 
 
 
 
 
 
 
Figure 3.21: AGE analysis of MiniPrep of pBks p33ING1∆C constructs. 2µl of construct MiniPrep 
from chosen colonies were digested simultaneously with Sal I and HindIII (10 U each) in the presence of 
2X of Y+/Tango Buffer for 4 hours at 35.5 C. 10µl of the digestion mixtures were loaded on the gel.  M: 
marker; u: undigested; d: double digested. 1% agarose gel. 
 
 Ligation products were transformed into super-competent E. coli cells and 
incubated overnight at 37°C. Positive colonies were selected and analyzed by restriction 
enzyme digestion. MidiPreps of the positive colonies were prepared.  
  
 
 
 
 
 
 
Figure 3.22: AGE analysis of MiniPrep of pcDNA3 p33ING1∆C constructs. 2µl of construct MiniPrep 
from chosen colonies  were digested simultaneously with KpnI and EcoRV (10 U each) in the presence of 
2X of Y+/Tango Buffer for 4 hours at 35.5 C. 10µl of the digestion mixtures were loaded on the gel.  M: 
marker; u: undigested; d: double digested. 1% agarose gel 
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Restriction digestion analysis showed that our cloning and subcloning was 
successful. At the end of this step both full-length and C-terminally deleted forms of 
p33ING1 are in the pcDNA3 expression vector, presented in Figure 3.22. 
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DISCUSSION 
 
The result of our study suggests that C-terminus region, particularly 
oligomerization domain of p53 is involved in interaction with p33ING1 in vitro. This 
conclusion can be drawn from results of our in vitro protein-protein binding assays 
assays with different deletion mutants of p53.  Oligomerization domain of p53 regulates 
the formation of p53 tetramer, form of active p53. This domain also contains a nuclear 
exclusion signal, which is hidden when the protein form tetramer. The results of GST 
pulldown assays and Far Western Blotting assays with p53 C-terminus deletion 
mutants, FuR6 and F6R6, suggest that, oligomerization domain of p53 protein is 
involved in interaction with p33ING1. The interaction between p53 and p33ING1 was 
inhibited when FuR6, lacking the C-terminus region of p53 (lacking the last 62 aa of 
p53), was used in vitro protein-protein interaction assays. When F6R6, which lacks 
only the oligomerization domain of p53 (lacking the aa between 331-357), was used in 
GST pulldown assay and Far Western blotting, we obtained the same results. Therefore, 
according to our data, oligomerization domain may be necessary for the interaction 
between p53 and p33ING1 . In one of our GST pulldown assays,  FuRz, a deletion mutant 
of p53 which has an intact oligomerization domain, does not interact with GST-p33. 
This deletion mutant construct of p53 lacks the 30 amino acids, which may hinder the 
formation of native 3D-structure of C-terminus region of the p53 required for the 
specific interaction with p33ING1. Also we showed that other members of the p53 
family, p63 and p73, interacts with p33ING1 and this interaction is primarily determined 
by C-terminus region of these proteins. This is the first time showing that p53 family 
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proteins are interacting with p33ING1. This result is not surprising since there is a 37% 
homology at oligomerization domain among p53 family members.  
p53 activity may be controlled by p33ING1. p33ING1 may behave as a Mdm2-like 
protein in the cell. It has been shown that different transcripts of ING1 gene regulates 
p53 activity differently; while p33ING1suppresses p53 activity by physically interacting, 
p24ING1 cooperates with p53 in the cell (Zeremski et al., 1999). Therefore by interacting 
with a oligomerization domain, p33ING1 may inhibit the tetramer formation of p53 and 
its transcriptional activity. Upon a stimulus, this may be a DNA damaging agent, the 
complex of p53-p33ING1 may dissociate and p53 can activate its target genes. It is very 
early to hypothesize about the place of p24ING1 in this scheme but it may help p53 when 
it is activated. 
 There are limited information about the regulation of the activities of p63 and 
p73 proteins and their involvement in growth arrest. Various numbers of proteins 
interact with p53 but only few proteins found to interact with the other members of the 
family (see for review Levrero, 2000). We have shown, as a first time, that one of the 
p53 interacting protein, p33ING1, interacts with both p63 and p73. As p33ING1 gene 
products are cell cycle regulated and involved in cell growth regulation, this data 
support the notion that p63 and p73 have roles in cell cycle regulation.  
 p33ING1 may interact with p63 and p73 through their oligomerization domain by 
this way it may inhibit the interaction between p53 and ∆Np63 and ∆Np73. Recent data 
suggests that p53 can be inactivated by ∆Np63 and ∆Np73 by physically interacting 
(Sayan et al., 2001; Irwin & Kaelin 2001). p33ING1 may behave as a “tuner protein” to 
regulate the activities of p53 family proteins. 
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Some of the p53 responsive promoters can be activated by p63 and p73 in 
different degrees (Kaghad et al., 1997, Yang et al., 1998, Jost et al., 1997). p24ING1 has 
been shown to involve in the activation of p21WAF1 promoter together with p53 
(Garkavtsev et al., 1998). Therefore p24ING1 may be involved in the regulation of the 
activation of p53 responsive promoters together with the family members. Also the 
strength of this activation may depend on these interactions.  
Different forms of ING1 gene product have been shown to have chromatin 
modifying activities or associate with proteins involved in chromatin modification. 
Therefore p33ING1 may be the way to link p53 family proteins to multiprotein 
complexes functioning in the regulation of chromatin modulation and gene activation. 
By its C-terminus domain, p33ING1 may recruit the multiprotein complexes to chromatin 
structure, while it’s N-terminus domain may interact with p53 family members. By this 
way, p33ING1 may make chromatin structure accessible for p53 family proteins.  
Mutations in p63 and p73 genes are rarely found in human cancers.  Functional 
inactivation of p63 and/or p73 may occur as a result of decreased expression of p33ING1 
or loss of function of this gene product rather than a mutation in these genes. 
Perspectives 
 The next step to this study is to use the C-terminus deletion mutant of p73 and 
test in in vitro protein-protein interaction assays. Also finer mapping of the interacting 
region of p63 is required. In our study we deleted both oligomerization domain and 
SAM domain of the p63 in the same construct, different deletion mutants of p63 should 
be prepared to examine the effects of these domains separately. To see whether 
oligomerization domain of p53 family proteins is the place where they interact with 
p33ING1, only the oligomerization domain of the family members could be cloned into 
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expression vectors and could be used in protein-protein interaction assays.  Our findings 
are in vitro results, these results should be repeated in vivo studies using different cell 
lines.  
 One further step is to do the whole study the other way around to find out the 
molecular determinants on the p33ING1 protein that enable the interaction. As a first 
step, we cloned the C-terminus deletion mutant of p33ING1 protein. This construct may 
be used in protein-protein interaction assays together with p53 family proteins. The next 
region that may have role in these interactions may be the N-terminus of the protein. 
Therefore cloning the N-terminus deleted mutants of p33ING1 may answer this question.  
 In our studies, we used alpha isoform of both p63 and p73, but there are at least 
six different isoforms of p63 and p73. Although the oligomerization domain is found in 
all of the isoforms, the SAM domain differs from one isoform to the other. Therefore 
examination of interaction of p33ING1 with different isoforms of p53 family may be 
another step to understand the consequences of this interaction. 
 One further step is to do same studies by using other ING1 gene products, 
p47ING1, p27ING1, and p24ING1. Since different ING1 isoforms have different effects on 
p53 regulated gene expression, the interaction between p53 family members and ING1 
isoforms may show various patterns.  
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APPENDICES 
Appendix A:  
LOCUS       AF044076                911 bp    mRNA    linear   PRI 04-FEB-1998 
DEFINITION  Homo sapiens candidate tumor suppressor p33ING1 (ING1) mRNA, 
            complete cds. 
ACCESSION   AF044076 
VERSION     AF044076.1  GI:2829207 
KEYWORDS    . 
SOURCE      human. 
  ORGANISM  Homo sapiens 
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; 
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. 
REFERENCE   1  (bases 1 to 911) 
  AUTHORS   Garkavtsev,I.A., Kazarov,A.R., Gudkov,A.V. and Riabowol,K. 
  TITLE     Suppression of the novel growth inhibitor p33ING1 promotes 
            neoplastic transformation 
  JOURNAL   Nature Genet. 14 (4), 415-420 (1996) 
  MEDLINE   97099452 
REFERENCE   2  (bases 1 to 911) 
  AUTHORS   Garkavtsev,I.A., Grigorian,I.A., Ossovskaya,V.S., Chernov,M.V., 
            Chumakov,P.M. and Gudkov,A.V. 
  TITLE    The candidate tumour suppressor p33ING1 cooperates with p53 in cell 
            growth control 
  JOURNAL   Nature 391 (6664), 295-298 (1998) 
  MEDLINE   98101645 
REFERENCE   3  (bases 1 to 911) 
  AUTHORS   Grigorian,I.A. and Gudkov,A.V. 
  TITLE     Direct Submission 
  JOURNAL   Submitted (21-JAN-1998) Molecular Genetics, University of Illinois 
            at Chicago, 900 South Ashland Avenue, Chicago, IL 60607, USA 
FEATURES             Location/Qualifiers 
     source          1..911 
                     /organism="Homo sapiens" 
                     /db_xref="taxon:9606" 
                     /chromosome="13" 
                     /map="13q34" 
     gene            1..911 
                     /gene="ING1" 
     CDS             45..884 
                     /gene="ING1" 
                     /codon_start=1 
                     /product="candidate tumor suppressor p33ING1" 
                     /protein_id="AAC00501.1" 
                     /db_xref="GI:2829208" 
                     
/translation="MLSPANGEQLHLVNYVEDYLDSIESLPFDLQRNVSLMREIDAKY 
QEILKELDECYERFSRETDGAQKRRMLHCVQRALIRSQELGDEKIQIVSQMVELVENR 
TRQVDSHVELFEAQQELGDTVGNSGKVGADRPNGDAVAQSDKPNSKRSRRQRNNENRE 
NASSNHDHDDGASGTPKEKKAKTSKKKKRSKAKAEREASPADLPIDPNEPTYCLCNQV 
SYGEMIGCDNDECPIEWFHFSCVGLNHKPKGKWYCPKCRGENEKTMDKALEKSKKERA 
YNR" 
BASE COUNT      228 a    255 c    305 g    123 t 
ORIGIN       
        1 gtcggaaagc cgcgccgagt cgccggggac ctccggggtg aaccatgttg agtcctgcca 
       61 acggggagca gctccacctg gtgaactatg tggaggacta cctggactcc atcgagtccc 
      121 tgcctttcga cttgcagaga aatgtctcgc tgatgcggga gatcgacgcg aaataccaag 
      181 agatcctgaa ggagctagac gagtgctacg agcgcttcag tcgcgagaca gacggggcgc 
      241 agaagcggcg gatgctgcac tgtgtgcagc gcgcgctgat ccgcagccag gagctgggcg 
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      301 acgagaagat ccagatcgtg agccagatgg tggagctggt ggagaaccgc acgcggcagg 
      361 tggacagcca cgtggagctg ttcgaggcgc agcaggagct gggcgacaca gtgggcaaca 
      421 gcggcaaggt tggcgcggac aggcccaatg gcgatgcggt agcgcagtct gacaagccca 
      481 acagcaagcg ctcacggcgg cagcgcaaca acgagaaccg tgagaacgcg tccagcaacc 
      541 acgaccacga cgacggcgcc tcgggcacac ccaaggagaa gaaggccaag acctccaaga 
      601 agaagaagcg ctccaaggcc aaggcggagc gagaggcgtc ccctgccgac ctccccatcg 
      661 accccaacga acccacgtac tgtctgtgca accaggtctc ctatggggag atgatcggct 
      721 gcgacaacga cgagtgcccc atcgagtggt tccacttctc gtgcgtgggg ctcaatcata 
      781 aacccaaggg caagtggtac tgtcccaagt gccgggggga gaacgagaag accatggaca 
      841 aagccctgga gaaatccaaa aaagagaggg cttacaacag gtagtttgtg gacaggcgcc 
      901 tggtgtgagg a 
// 
 
Some Biophysical Data of p33ING1 calculated from sequence data:  
 
net charge: -2  
hydrophobicity: 0.5710  
insolubility factor: 1.4121  
isoelectric point: 7.13 
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Appendix B: 
LOCUS       NM_001564              1078 bp    mRNA    linear   PRI 31-OCT-2000 
DEFINITION  Homo sapiens inhibitor of growth family, member 1-like (ING1L), 
            mRNA. 
ACCESSION   NM_001564 
VERSION     NM_001564.1  GI:4504694 
KEYWORDS    . 
SOURCE      human. 
  ORGANISM  Homo sapiens 
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; 
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. 
REFERENCE   1  (sites) 
  AUTHORS   Shimada,Y., Saito,A., Suzuki,M., Takahashi,E. and Horie,M. 
  TITLE     Cloning of a novel gene (ING1L) homologous to ING1, a candidate 
            tumor suppressor 
  JOURNAL   Cytogenet. Cell Genet. 83 (3-4), 232-235 (1998) 
  MEDLINE   99172097 
COMMENT     REVIEWED REFSEQ: This record has been curated by NCBI staff. The 
            reference sequence was derived from AB012853.1. 
            Summary: ING1L encodes inhibitor of growth 1-like, so named  
            because of its considerable similarity to the putative tumor- 
            suppressor gene ING1. ING1 is thought to exert its effects through  
            interaction with p53, while the function of ING1L remains unknown. 
            COMPLETENESS: incomplete on the 3' end. 
FEATURES             Location/Qualifiers 
     source          1..1078 
                     /organism="Homo sapiens" 
                     /db_xref="taxon:9606" 
                     /chromosome="4" 
                     /map="4q35.1" 
     gene            1..1078 
                     /gene="ING1L" 
                     /db_xref="LocusID:3622" 
                     /db_xref="MIM:604215" 
     CDS             92..934 
                     /gene="ING1L" 
                     /codon_start=1 
                     /db_xref="LocusID:3622" 
                     /db_xref="MIM:604215" 
                     /product="inhibitor of growth 1-like" 
                     /protein_id="NP_001555.1" 
                     /db_xref="GI:4504695" 
                     
/translation="MLGQQQQQLYSSAALLTGERSRLLTCYVQDYLECVESLPHDMQR 
NVSVLRELDNKYQETLKEIDDVYEKYKKEDDLNQKKRLQQLLQRALINSQELGDEKIQ 
IVTQMLELVENRARQMELHSQCFQDPAESERASDKAKMDSSQPERSSRRPRRQRTSES 
RDLCHMANGIEDCDDQPPKEKKSKSAKKKKRSKAKQEREASPVEFAIDPNEPTYCLCN 
QVSYGEMIGCDNEQCPIEWFHFSCVSLTYKPKGKWYCPKCRGDNEKTMDKSTEKTKKD 
RRSR" 
     variation       130 
                     /allele="T" 
                     /allele="C" 
                     /db_xref="dbSNP:8872" 
     variation       complement(130) 
                     /allele="A" 
                     /allele="G" 
                     /db_xref="dbSNP:1132711" 
     misc_feature    734..841 
                     /note="PHD; Region: PHD-finger" 
BASE COUNT      356 a    206 c    280 g    236 t 
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ORIGIN       
        1 tccaagctga gctgagggcc cgcggcggcc gcggccggtg catgtgcggc tgctggatgc 
       61 ggaggcggcg gcgacggcgc ggatcggcag gatgttaggg cagcagcagc agcaactgta 
      121 ctcgtcggcc gcgctcctga ccggggagcg gagccggctg ctcacctgct acgtgcagga 
      181 ctaccttgag tgcgtggagt cgctgcccca cgacatgcag aggaacgtgt ctgtgctgcg 
      241 agagctggac aacaaatatc aagaaacgtt aaaggaaatt gatgatgtct acgaaaaata 
      301 taagaaagaa gatgatttaa accagaagaa acgtctacag cagcttctcc agagagcact 
      361 aattaatagt caagaattgg gagatgaaaa aatacagatt gttacacaaa tgctcgaatt 
      421 ggtggaaaat cgggcaagac aaatggagtt acactcacag tgtttccaag atcctgctga 
      481 aagtgaacga gcctcagata aagcaaagat ggattccagc caaccagaaa gatcttcaag 
      541 aagaccccgc aggcagcgga ccagtgaaag ccgtgattta tgtcacatgg caaatgggat 
      601 tgaagactgt gatgatcagc cacctaaaga aaagaaatcc aagtcagcaa agaaaaagaa 
      661 acgctccaag gccaagcagg aaagggaagc ttcacctgtt gagtttgcaa tagatcctaa 
      721 tgaacctaca tactgcttat gcaaccaagt gtcttatggg gagatgatag gatgtgacaa 
      781 tgaacagtgt ccaattgaat ggtttcactt ttcatgtgtt tcacttacct ataaaccaaa 
      841 ggggaaatgg tattgcccaa agtgcagggg agataatgag aaaacaatgg acaaaagtac 
      901 tgaaaagaca aaaaaggata gaagatcgag gtagtaaagg ccatccacat tttaaagggt 
      961 tatttgacta ttatataatc cgtttgcttt cagaaaatgt tttagggtaa atgcataaga 
     1021 ctatgcaata attattaatc attagtatta atggtgtatt aaaagttgtt gtactttg 
// 
 
 
